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ABSTRACT

The effects of carnitine supplementation on AFB 1 toxicity in male Sprague-Dawley
rats were studied. Rats were fed Purina Rat Chow with or without camitine supplement
for 6 weeks. In Experiment 1, the rats (n=20) were dividetinto 4 groups, namely .
nonsupplemented control (NSC), nonsupplemented AFB 1 (NSA), camitine supplemented
control (CSC) and camitine supplemented AFBl (CSA) groups. The NSA and CSA
groups were given an oral dose of [3H]AFB 1 ( 1 mg/kg) 6 h before sacrificing. In
Experiment 2, the rats (n= 1 0) were divided into NSA and CSA groups and were sacrificed
24 h post-AFB 1 administration. Concentrations of total lipid, triglycerides, camitine and
AFB I-macromolecules adduct formation, and urinary excretion of AFB 1 were measured.
Carnitine supplementation prevented increase in hepatic total lipid and triglyceride
concentrations caused by AFB 1. In the plasma, supplemental camitine prevented the
AFB I-induced decrease in the .¥11ount of total lipid and triglyceride. Carnitine
supplementation reduced AFB 1 covalent binding to hepatic macromolecules, namely ��A,
DNA, and protein. The c,:mcentrations of RNA, DNA, and protein in the CSA rats were
significantly higher than in the NSA animals 24 h post-AFB 1 treatment. [3H]AFB I
radioactivity was found in the acid insoluble acylcamitine (AIAC) fraction. Carnitine
supplement, however, had no significant effect on the amount of [3H]AFB 1 associated
with AIAC. AFB 1 treatment of rats 6 h prior to sacrifice caused significant increase in the
liver nonesterified camitine (NEC), acid soluble acylcarnitine (ASAC), and total camitine.
The amounts of AFB! in the liver, kidney and plasma were not significantly different in the
NSA and CSA animals. The concentration of AFB 1 excreted in the urine was also not
statistically differe_nt in the CSA and NSA rats. In conclusion, carnitine supplemention
offered protection against AFB I-induced fatty liver and AFB I-macromolecule adducts
formation.
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CHAPTER 1
INTRODUCTION
Aflatoxins, a group of secondary metabolites of Asper�llus flaYlll and.A.
parasiricus, are often found to contaminate food and feed supplies. Epidemiological studies
and clinical findings especially in developing countries such as Uganda (1), Kenya,
Swaziland, Mozambique, and Thailand (quoted from 2) showed incidences of liver cancer
correlated to consumption of aflatoxin-contaminated food. In India, acute toxicity of
aflatoxins due to consumption of aflatoxins-contaminated maize affected 397 patients, of
which, 106 died (3). Analysis on the maize samples showed that the patients might have
consumed 2 to 6 mg of aflatoxins per day for several weeks. Recently, acute toxicity of
aflatoxins have been reported as the cause of deaths of eleven children in Malaysia who ate
rice noodles that were contaminated with aflatoxins (4).
Aflatoxin B 1 (AFB 1) is the most abundant and toxic of all aflatoxins. It has been
found to be hepatotoxic (5), hepatocarcinogenic (6), and teratogenic (7). AFB1 in
. combination with other aflatoxins has been reported to be immunosuppresive (8). The liver
is the main target organ of aflatoxin toxicity. The signs of liver damage caused by AFB 1
include fatty liver, bile duct hyperplasia, and finally necrosis (9).
Fatty liver is also caused by acute and chronic alcohol intoxication in animals and
humans (10, 11, 12) which has been attributed to increase lipogenesis and/or impaired fatty
acid oxidation. Camitine, a vitamin-like substance whose main function is in
intramitochondrial transport of fatty acids for beta-oxidation, has been shown to ameliorate
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ethanol-induced fatty livers in rats (13, 1 4, 1 5). Therefore, it was thought desirable to
examine if camitine supplement could prevent the fatty liver caused by AFB 1 .
AFB 1 needs to be activated by mixed function oxygenase system to fonn an AFB 1 epoxide which can covalently bind to electrophilic centers (N, 0, and S atoms) of
macromolecules such as DNA, RNA, and protein (2). These covalent bindings, especially
to the DNA have been linked to AFBt carcinogenicity. Since carnitine has a electrophilic N
center, it is possible that AFB1-epoxide could bind to camitine, and in doing so, spare the
macromolecules from the electrophilic attack of AFB1. Camitine has been reported to
lessen the side-effects of therapeutic drugs ( 1 6) via conjugation to the drugs (17).
In light of these observations, the following objectives were setforth for this study:
1 . To detennine the effects of supplementary camitine on AFB 1 -induced fatty liver;
2. To study the effects of supplementary carnitine on AFB1-macromolecules
binding;
3. To determine of effects of AFB 1 on plasma and liver carnitine concentrations and
[3H]AFB 1 associated with carnitine.
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CHAPTER 2

REVIEW OF LITERATURE

2. 1 AFLATOXINS
2, 1.1 History
Aflatoxins are a group of secondary metabolites of Asperiillus flayus and A..

parasiticus. These mycotoxins are often found to contaminate food and feeds (such as
milk, com, peanuts, cottonseed, rice, barley, and many others) as well as grain-fermented
beverages and edible animal tissues (18). These toxins have been considered as
unavoidable contaminants since they cannot be totally eliminated or prevented from
contaminating food or feeds even with the most modem technology available today (19).
The problem of aflatoxin contamination has long been recognized and limits or action levels
for the toxin content in agricultural commodities have been set since 1965.
Aflatoxins were first discovered in 1960 when a series of outbreaks in poultry and
fish occurred in different parts of the world. One of the worst outbreaks was known as a
"turkey X" disease which had caused many deaths of turkeys and ducklings in the United
Kingdom due to consumption of contaminated Brazilian peanut meal (quoted from 9). The
acute symptoms of the disease included weakness, loss of appetite, lethargy, and
"distinctive attitude of the head and neck" at the time of death. Histologically, the disease
caused an acute liver necrosis and bile duct proliferation. Consumption of contaminated
com, peas and cotton-seed had also been reported as the cause of outbreaks analogous to
the turkey X disease in farm animals and fish (quoted from 9).
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In 196 1, Sargeant et al. (20) isolatedA � from the contaminated Brazilian
peanut meal. The investigators found that when the fungus was reinoculated into peanut
meal, it produced toxins similar to those found in the contaminated Brazilian meal. The
name "aflatoxins" (AF) was given to the toxins that had been extracted and isolated The
letters B and G refer to the toxin's color under UV light (B--Blue; G--Green), and the
subscripts relate to their position on thin-layer chromatography plates. Currently, over a
dozen aflatoxins have been identified.

2.1.2

Structure and Toxicity Differences of Aflatoxins
Aflatoxin B1(AFB1), B 2 (AFB2), Gt (AFGt) and G2 (AFG2) are the four major

naturally occuring aflatoxins. The structure of aflatoxins consists of a coumarin nucleus
attached to a bifuran and either a pentanone (AFB 1 and AFB2) or a six-membered lactone
(AFGt and AFG2) (refer to Figure 2. 1). AFMt, AFM2, AFGMt, and AFGM2 are the
!Detabolites produced in microbial and/or animal systems when they are exposed to the
above naturally occuring aflatoxins (22). AFB1 and AFGt were found to be more toxic to
rats and ducklings than AFB 2 and AFG2 (23). As for carcinogenicity, AFBt was more
potent than AFG1, which in turn, was more carcinogenic than AFB 2 (24).
Hydroxy lated derivatives of aflatoxins are AFM 1, AFM2, AFGM 1, AFB 2a,
AFG2a, parasiticol, aflatoxicol, AFPt, and AFQ1. The toxicity of AFM 1 is similar to
AFBt but less carcinogenic. AFG2a is relatively non-toxic, and it has been identified as
AFB1 hemiacetal, aflatoxin W (AFW) and hydroxydihydroaflatoxin (9). Parasiticol
(AFB3) has an ethanol moiety in place of the terminal pentanone ring. It is as toxic as
AFB 1 to duckling but less toxic than AFB1 to chick embryos . Aflatoxicol (A.Ro) is a
degradation prcxluct of AFB.I and has been found to be highly toxic and carcinogenic to
fish (24).
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AFP 1 is produced when AFB 1 undergoes 0-demethylation in animals. AFP 1 LD 50
· value to mice is about 15 times less than that of AFB 1 (25). AFQ 1 , which contains a
hydoxyl group at the C-3 position, has been isolated in vitro using monkey and human
liver microsomes (25,26). Aflatoxin D1 and D2 are two major degradation products of
AFB 1 when detoxified with ammonia.
2. 1 .3 AFB1 Metabolism
The metabolism of AFB 1 , in vivo or in vitro, may result in many different
derivatives of the toxins. In vitro, AFB 1 undergoes at least five types of metabolic
reactions with liver enzyme preparations, namely reduction, hydroxylation, hydration, 0demethylation and epoxidation (see Figure 2.2) (22,27). The products of the respective
reactions are aflatoxicol, AFM 1, AFQ 1 , AFB2a, AFP 1 , and AFB 1 -2-3 -oxide. Except for
the epoxide, all the metabolites contain an OH- group which can be conjugated with
glucuronic acid and sulfate. This conjugation results in detoxification of the aflatoxins by
the formation of water-soluble aflatoxin esters which can be excreted in the urine or bile
(22).
AFB 1 requires metabolic activation by mixed-function oxygenase (MFO) system to
form the epoxide derivative that is responsible for AFB 1 toxicity and carcinogenicity (22).
Once formed, the epoxide can either cause an electophilic binding on nucleophiles (such as
nucleic acids and proteins); or be conjugated with reduced gluthathione and be detoxified;
or be hydrolyzed to form the 2, 3 -dihydrodiol of AFB 1 ; or be reduced to the hemiacetal
form (22).
The major adduct formed between AFB 1 and DNA and RNA has been identified as
the 2, 3 -dihydro-2-(N7-guanyl)-3 -hydroxy-AFB 1 (28). The covalent binding of AFB 1 to
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macromolecules DNA, RNA, protein) has been suggested as the main mode of acute
toxicity and carcinogenicity of AFB 1 (22). The half-life of AFB 1 -DNA adducts is reported
to be approximately 1 2 h, after which they are rapidly excreted in the urine (29).
2. 1 . 4 Toxicity and Carcinogenicity of AFB1
AFB 1 is the most toxic, most abundant, and therefore, the most studied of all
aflatoxins. It constitutes about 75% of the aflatoxins found in naturally contaminated
agricultural commodities (22). It has been reported to be hepatotoxic (5),
hepatocarcinogenic (6), teratogenic (7), mutagenic (30), and immunosuppressive (8). The
liver is the main target organ for AFB 1 toxicity and carcinogenicity. However, AFB 1 has
been found to cause tumors in kidneys of rats (3 1 ).
The acute toxicity of AFB 1 has been shown to cause severe morbidity and deaths in
laboratory (5) and farm (9) animals, and humans (3,4) (refer to Table 2 . 1 for LD50 of
AFB l on different animals). The covalent binding of AFB 1 with DNA was linearly
correlated with the susceptibility of animals such as rats and trout to liver cancer (32). It
has been documented to have carcinogenenic effects on mice, rats (23), ducks (33), trout
(24) and primates (6). A number of epidemiological studies have also shown a strong
correlation between dietary aflatoxin consumption and liver cancer rates in humans ( 1 , 2,
29, 3 2) (see Table 2. 2 .) Virtual safe dose of aflatoxin in human was estimated to be 0. 2 64
ng/kg/d or less (3 2).

2. 1,4,a Species and Gender Differences
Metabolism of AFB 1 in different species of animals may produce different
metabolites of AFB 1 . As a result, the susceptibility to acute toxicity and carcinogenicity of
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Table 2. 1 Median Lethal Dose of AFB 1 .

Species

mg/kg, oral

Rabbit

0. 3

Duckling

0. 3

Cat

0.6

Pig

0.6

Trout

0. 8

Dog

1 .0

Guinea Pig

1 .4

Sheep

2.0

Monkey

2.2

Mouse

9.0

Hamster

1 0.2

Chick

1 1 .5

Male Rat
Female Rat

7.2
1 7 .2

Source: Marasas et al. (1987). Aflatoxicosis. In: Mycotoxicology: Introduction to the
Mycology, Plant Pathology, Chemistry, Toxicity, and Pathology of Natural Occuring
Mycotoxicosis in Animals and Man. pp. 25-31 , Pennsylvania State University Press,
University Park, PA.
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Table 2. 2 Aflatoxin Ingestion and Liver Cancer Incidence in Humans.

Cases o( liver cancer in adults ( > 15 years old)

Population

Kenya

High alti1ude
:vf edium ahitude
Low altitude
Swaziland

Highveld

Middleveld
Lebombo
Lowveld
Thailand•
Songkh:ila
Ratburi
Moumbique"

Dietary
ana,o"in
intake
(ng,kg or
body weight
per day,

3-5

Women

Men
SoJl00.000
population
per year

I

Incidence

3. 1
1 0.8

(>-8
1 0- 1 5

13

16

1 2.9

5-9

9
24
4

1 4.8

9- 1 4

1 5-20
43-53
5-8
45-77
:?:?:?

35

7.0

1 8.7
26.7

35.0

NoJI00.000
population
per year

Incidence

0

0
3.3

9

5.4

2

1 .4
2.:?
0

6

5

o.
7

5.6

15.7

Nor�: Data were compiled for I ye:ir in Thailand. 3 ye:ics in Mozambique. and 4 ye:irs in K�nya :ind S waziland.
• Statistics for the total popul:i1ion were c:ises per I 00.000 population wi1h an incidence of 6.0. In Ra1buri. Thailand.
staliMics for the 101al population were two cases per 1 00.000 popul:i1ion per ye:ir with an incidence of 2.0.
• Incidence for che to1al popul:ition was ZS.4 cases per 1 00.000 population per ye:ir.

Source: Groopman et al. ( 1 988). Aflatoxin exposure in human populations:
Measurements and relationships to cancer. In: CRC Critical Reviews of Toxicology,
Volume 19, Issue 2, pp. 1 1 3- 1 45.
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AFB 1 varies from species to species. Also, the liability of acute toxicity and
carcinogenicity are not dependent on one another (9).
Rats were found to be highly susceptible to carcinogenic effects but moderately
susceptible to acute toxicity of AFB 1 . On the other hand, guinea pigs were more
susceptible to acute effects but less susceptible to carcinogenic effects (34). Monkeys were
relatively resistant to carcinogenic effects of AFB 1 but were quite sensitive to acute effects
compared to rats and mice. Also, of the three species, monkeys had the lowest AFB 1
excretion rate, and mice were quite resistant to both acute and carcinogenic effects (35).
AFB 1-binding to liver RNA and protein was higher in guinea pigs than rats. This
corresponds with the higher susceptibility of guinea pigs than rats to acute toxicity of
AFB 1 . In addition, the lower AFB 1 -DNA binding in guinea pigs than in rats indicates that
rats are more susceptible to the carcinogenic action of AFB 1 . Mice had the lowest AFB 1 macromolecule adducts formation which comsponded to their resistance to both acute and
carcinogenic effects (36).
Male rats have higher AFB 1 -DNA binding than female rats which indicates that
female rats are relatively resistant to carcinogenic action of AFB 1 (37). It was suggested
that the increase in induction of detoxification enzymes in females rats, may have a
protective effect on AFB 1 toxicity. In humans, cases of acute aflatoxicosis were twice as
many in males than in females (3).

2. 1.4,b Symptoms of Acute Aflatoxicosis
The general symptoms of acute aflatoxicosis in cattle, dogs, pigs, and poultry were
decrease in weight, general unthriftiness and inappetence .(38). Signs of liver injury
include icterus, edema, hemorrhage, and ascites. Death rates are usually high and may be
preceeded by convulsions and ataxia. Histopathological studies on livers of laboratory
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animals showed fatty degeneration, necrosis, fibrosis, and extensive bile-duct proliferation
(38). In humans, symptoms of acute aflatoxicosis due to consumption of contaminated
maize included vomitting, anorexia, icterus, ascites, and sometimes edema. Death usually
occurred after massive gastrointestinal hemorrhage (3). Similar symptoms were also seen
in dogs that had eaten the contaminated maize.
2.1 .4.c AFB1 and Lipids Metabolism
AFB 1 has often been reponed to interfere with lipid metabolism in both animals and
humans. Lipid synthesis was inhibited in ducklings (39) and chickens (40) due to AFB 1 .
In ducklings, the toxin significantly suppressed growth and lowered liver weigl"a, but it
increased total lipids content in the liver. The toxin showed a dose-dependent inhibition of
lipids synthesis by reducing the incorporation of 1 4c-acctate into long-chain fatty acids in
chickens (40). Triglycerides, total phospholipids, and free and esterified cholesterol in
chicken's blood serum were significantly lowered with a dose of aflatoxin that was too
small to inhibit growth. However, liver lipids were significantly increased (4 1 ).
In rat liver, AFB 1 increased cholesterol levels while inhibiting cholesterol synthesis
(42). The investigators suggested that the inhibition of cholesterol synthesis was specific
and not the result of general hepatic injury. Serum cholesterol levels were significantly
decreased. Phospholipids synthesis was also inhibited in liver preparation of rats
previously injected with aflatoxin (43).
Aflatoxins have been found to cause steatorrhea in chickens. Pancreatic lipase,
primary fat digestive enzyme, and bile, important for lipid digestion and absorption, were
decreased significantly in this case. The authors concluded that the steotorhea was due to
impairment in lipid digestion produced by the aflatoxins added to the diet (44).
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AFB1 had also attenuated lipids synthesis in humans. Using human skin
specimens, Black et al. (45) found that incorporation of radio-labeled acetate into total
lipids, phospholipids, free sterol, and neutral fat was significantly inhibited. The authors
also suggested that the inhibition was specific and not due to general liver toxicity.
Overall, the investigators that studied the effects of aflatoxins on lipid metabolism
concluded or suggested that i) the increase in liver lipids and decrease in serum lipids was
due to inhibition of lipid transport from the liver to the blood and peripheral tissues and not
. due to increase in lipogenesis (39,42); ii) the inhibition was general and not specific to
lipid fractions (4 1); iii) the impairment in lipogenesis was due to a decrease in the formation
of enzymes involved in fatty acid biosynthesis such as fatty acid synthetase (40).

2, 1.5 AFB I-Macromolecule Adducts and Diet/Dru� Interactions
Many studies have been carried out to determine the effects of various food/nutrients
and drugs/xenobiotics on the AFB 1-macromolecule addu�ts formation. The major
objective of these investigations was to find if the nutrients and drugs/xenobiotics could
inhibit the adducts formation, and thus, preventing the carcinogenic effects of AFB 1.

2.1,5.a Food Nutrients
Fat-Soluble Vitamins
Quite a range of vitamins and vitamin analogs that have been tested on AFB 1 macromolecule adducts formation. Bhattacharya et al. have reported comprehensive
studies on the effects of various vitamins on in vitro adducts formation (46) and AFB 1
mutagenicity ( 47).
Vitamin A supplementations in rats inhibited AFBl -DNA adducts formation (48).
The protective effects of retinoids such as retinol, retinal, retinoic acid, and retinyl esters on
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AFB 1 carcinogenicity was due to inhibition of ONA adducts formation mediated by
microsomal MFO enzymes (46,49). Retinol had the same inhibitory effect on the
formation of AFB 1-protein adducts (49). As for mutagenicity, retinol, and retinoic acid
were shown to inhibit mutagenesis due to AFB 1 in the Salmonella typhimurium system
(47,50). It was suggested that the protective effects of vitamin A were the result of
interaction with microsomal enzymes; resulting in interference with the activation of AFB 1
(47,49). Recently, vitamin A has been shown to be imponant in regulating gluthathione-S
transferase (GST) activity involved in the detoxification process. Vitamin A
supplementation increased the GST activity and the reverse occurrcd when vitamin A was
deficient (48).
Vitamin E supplementation had no significant effect on in vivo covalent binding of
AFB 1 to liver macromolecules in rats. However, a combined deficiency of vitamin E and
selenium decreased DNA, RNA, and protein adducts in the rats (5 1). Yet, the same
investigators reported that the combined deficiency of vitamin E and selenium increased the
DNA and RNA adducts in chicks (quoted from 5 1). Vitamin E, as well as menadione, a
water soluble synthetic vitamin K, both inhibit AFB 1-induced mutagenisis in Ames
bacterial system (50).

warer-Soluble Vitamins
Riboflavin, rifboflavin-5'-phosphate (FMN), and flavin adenine dinucleotide (FAD)
inhibited AFB I-DNA adduct formation in vitro (46). Riboflavin being more effective than
FMN and FAD. Vitamin C, vitamin B6 and thiamin had no significant effect on the DNA
adducts production (46). However, vitamins C, B6, B 12 and folic acid significantly
inhibit mutagenisis in bacterial systems (46,47). The inhibition by vitamin C; however,
was not as great compared to fat-soluble vitamins.
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Amino Acids and Protein
A diet marginally deficient in methionine (which was also deficient in choline and
lacking in folacin) depressed DNA and RNA adducts formation in rat liver. Protein adduct
was not affected by the diet. The inhibition of AFB 1 -nucleic acid adducts by the
marginally lipotrope-deficient diet was due to the decrease in :MFO activities and not due to
an increase in gluthathione levels (52). The authors concluded that the earlier reported
AFB 1 -induced tumorigenesis caused by marginally deficient lipotrope diets (53) was not
due to an increased in activation of AFB 1 .
Sulfur-containing amino acids such as cysteine, N-acetylcysteine, cystint�,
methionine, and reduced or oxidized gluthathione inhibited AFB 1 mutagenicity in microbial
systems. Cysteine and N-acetylcysteine were more potent inhibitors than gluthathione.
The investigators suggested that the inhibition was due to the amino acids interfering with
the activation of the AFB 1 (54).

..Eal
Both saturated and unsaturated dietary fats did not significantly affect the adduct
formation and the production of the AFB1-cpoxide in rat livers (55). In a similar study,
high polyunsaturated oil (com oil) increased the incidence of liver ·cancer in rats exposed to
AFB 1 as compared to rats fed with saturated oil (beef fat). The cancer incidence was
higher when the com oil was fed together with or after the exposure to AFB 1 than when
corn oil was fed after the AFB 1 dose. An increase in induction of AFB 1 activation by com
oil was suggested for the high incidence of cancer (56).
The presence of long chain fatty acids at their physiological concentrations increased
the strength of AFB 1 -albumin binding considerably (57). Albumin serves as the major

17
transpon mechanism of AFB 1 in blood since very little AFB 1 was bound to other blood
proteins (58). This binding affinity (Ka) is increased 3 fold by increasing the pH from 6 to
9. The presence of palmitic, stearic, and oleic acids (the most abundant plasma fatty acids)
at the concentration range of 0.5 to 2.0 moles/mole albumin funher increased the albumin
binding of AFB 1 to greater than 4 fold at pH 7 .4 (57).

Trace elements
Copper decreased AFB 1 -DNA binding in vitro (46). Deficiency and excess of
selenium decreased the adducts formation in rats. In chicks, however, excess of selenium
did not affect the amount of adducts formed (5 1 ).
Copper, manganese, zinc, and selenium were effective in depressing in vitro
mutagenesis induced by AFB 1 . Copper was the most potent of the elements tested. To a
lower extend, icxline, molybdenum, cobalt, and iron were antimutagenic. It was suggested
that the inhib�on was due to interaction of the trace elements with the microsomal enzymes
( 59 ) .

2. 1.5.b Caloric Restriction
There has been considerable interest on the effect of caloric restriction on cancer
promoting chemicals and compounds. It has been reported that rats fed with 60% of the
food consumed by the ad libitum animals had lower AFB 1 microsomal activation, lower
AFB 1 -DNA adducts, faster plasma clearance, and increased excretion of AFB 1 in urine
than the ad libitum fed animals. From these results, the authors concluded that 40% food
restriction promoted a more efficient AFB 1 metabolism (60).
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2, 1,5,c Cruciferous Ye�etables
Cruciferous vegetables have been shown to enhance detoxification of xenobiotics by
inducing xenobiotic-metabolizing enzymes in animals and humans (quoted from 6 1).
Increased consumption of these vegetables, for example broccoli, cabbage, cauliflower,
and Brussel sprouts has been related to a reduced risk of bladder, colon and rectum cancers
( 62 ) .

Brussel sprouts may have a protective factor against the AFB 1 carcinogenicity. This
vegetable significantly decreased AFB 1-DNA binding and increased GST activities in rats.
lndole-3-carbinol, a compound found in cruciferous vegetables did not have much effect on
the DNA binding to AFB 1 or the OST activity (6 1). The same investigators also found
that the route of administration of AFB 1, intragastric or intraperitoneal, did not change the
inhibition of AFB 1-DNA binding. Thus, they concluded that the small intestine may not
play an important role in the AFB 1 metabolism. However, in another study that utilized
trout, 1000 and 2000 ppm of indole-3-carbinol were shown to strongly depress AFB 1 D NA adducts formation (63). R-Ooitrin, another compound common in cruciferous
vegetables, also exhibited anticarcinogenic role by inhibiting AFB 1 -DNA binding,
increasing OST activity, and enhancing biliary excretion of AFB 1 in rats (64).

2.1.5.d Plant flavonoids and Phenolic Compounds
Several derivatives of five major plant flavonoids, namedly, flavone, flavonol,
isoflavone, and flavonol have been tested on AFB 1 -DNA binding and activation of AFB t
(65). Most of the flavonoid derivatives significantly inhibited the adducts formation.
However, flavonols had the most potent effect on the inhibition of the binding and
activation of AFB i. Flavonols also showed greater inhibition of AFB 1 mutagenicity in
bacterial systems (66).
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Phenolic compounds have also been shown to have protective effects on
mutagenicity caused by AFB 1 . Gallic acid, chlorogenic acid, caffeic acid, dopamine, p
hydroxybenzoic acid, and salicyclic acid depressed AFB 1 -induced mutagenicity in a
bacterial system containing rat-liver microsomes. The inhibition occurred when the
compounds and AFB 1 were administered concwrently (67).

2.1.5,e Antioxidants
Antioxidants, such as butylated hydroxyanisole (BHA) and butylated
hydroxytoluene (BHT), are chemicals commonly added to food to prevent spoilage due to
oxidation. Rats fed a BHA added diet (7500 ppm) had significantly lower AFB 1-DNA
binding, higher GST activities, and higher biliary excretion of AFB 1 (64). In trout;
however, BHA had no effect on liver tumor incidence, AFB 1 -DNA binding, and AFB 1 gluthathione conjugation (68). These results have led to suggestion that in mammals, an
increase in the gluthathione conjugation is the basis for BHA inhibition of AFB 1
carcinogenicity. In in vitro system; however, BHA as well as BHT markedly inhibited
AFB 1 -DNA binding (46).

2, 1,5 ,f Pruis and Other Compounds
Pretreatment of an anti-seizure drug, phenobarbital, in rats increased AFB 1
activation in vivo and in vitro (69,70). However, it also induced GST activity and
enhanced the excretion of biliary AFB 1 -gluthathione conjugate; therefore, the overall
hepatic binding of AFB 1 to DNA is reduced Ethanol pretreatment on the other hand,
increased the activation of AFB 1 but not the activity of OST. Thus, ethanol pretreatment
increased binding of AFB 1 to DNA and RNA (7 1 ).
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Cortisol pretreannent in female rats significantly increase the acute hepatotoxicity
induced by AFB 1 . This effect of cortisol was dose dependent and supponed by increased
monality rate, hepatic triglycerides, and binding of AFB 1 to DNA and protein (72). This
effect was perhaps mediated via increased metabolism of AFB 1 to its epoxide derivative as
well as hydroxylated derivatives (AFM 1 and AFQ l ) in microsomes since activity of aniline
hydroxylase was elevated in cortisol pretreated rats.

2,2 CARNITINE
2.2, 1 History
Camitine was first discovered by two Russian scientists from muscle extracts in
1 905 (quoted from 73). It was named carnis , which is a Latin word for flesh or meat. In
the 1 940's, carnitine was found to be essential for the mealworm by Fraenkel, and was
named Vitamin B t . In the late 1 950's and early 60's, it was discovered that camitine is
involved in the transportation of fatty acids into the mitochondria for 6-oxidation (74).
However, not until 1 973 did camitine gain much attention and investigation, that is, when
the first camitine deficient patient was described by Engel and Angelini (75).

2,2.2 Chemisny and Dietary Sources
Carnitine is a quarternary amine and is very similar to choline and amino acids.
However, unlike amino acids, it is not involved in protein synthesis. Chemically, it is
known as 3-hydroxy-4-N-trimethy!amino butyric acid. It exists in two forms or isomers,
L-camitine and D-camitine. Only the L-camitine is biologically active. The D-isomer is
not only inactive, it has been reponed to depress L-camitine utilization (76). Carnitine is
not essential for humans since it can be produced in the body, and therefore, is not
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considered a vitamin. Muscle tissue of animals, lamb liver, yeast, and milk are very good
sources of dietary carnitine. Most vegetables and grains such as cauliflower, cabbage,
spinach, barley, and rice contain very little or no camitine. More detailed reviews are
available on carnitine history, biosynthesis, dietary sources and functions (73,76,77).

2,2.3 Camitine Biosynthesis
The biosynthesis of carnitine starts from two essential amino acids, lysine and
methionine, in a five step pathway involving frye �ferent enzymes. Niacin, vitamin B6,
vitamin C, and iron are also required for biosynthesis of carnitine in animals (quoted from
77). (Refer to Figure 2.3 for the complete pathway of camitine biosynthesis.)
In rats, the first 4 steps of the pathway occur in the liver, kidney, skeletal muscle,
cardiac muscle, testis, and epididymis. However, the final step occurs only in rat liver
(78). The human brain, liver, kidney, heart, and skeletal muscle can conven N
trimethyllysine to 4-N-trimethylamino butyric acid; but only the liver, kidney, and brain can
convert 4-N-trimethylamino butyric acid to camitine (79). This is because the enzyme
catalyzing the final step, butyrobetaine hydroxylase, is present only in the tissues where
carnitine is finally synthesized. Therefore, carnitine must be transponed to those tissues
that do not have the final enzyme.

2,2,4 Functions of Camitine
The main function of camitine is the transportation of long-chain fatty acids from the
cytosol into the mitochondria to allow beta-oxidation to take place. In brief, other functions
of carnitine include metabolism of branched-chain amino acid, initiation of ketogenesis,
thermogenesis in brown adipose tissue of infant rats, stimulation of gluconeogenesis,
facilitation of urea removal from blood and tissue, the removal of shon-chain and medium-

22

lysine
step I
(�ted 3 times)

SAM <S-adenosyl methionine)
SAM (S-admosyl m�rhionin�
lysin� 11111hyltransf�ras�)
N-trimethyllysine

step 2

C

ascorbic: acid. iron, oxygen.
and aJpha-keto glul31'3te
N-trimnhyllyliM lma-hydroxylase
dehydroascorbic acid.
iron.
and succirwe

c�.

. N-aimethyl-3:
hydroxy lysine
aldolas�
(vitamin 86 is cofactor)
4-N-trimethylamino
butyraldehyde

NAO •

step 4

( d�h�rog�nas�
NAOH + H 1-

-�4-N-trimethylamino
hutyric acid

1

ascorbic acid. iron. oxygen, and
( a!pha-keto gJUW3tC
b,uyrobeiaine hydrozylu�
dehydroascorbic acid,
iron.
and succ:inatc

.....

c�.

. camitine
(3-hydroxy-4-N
trimcthylamino
butyric: acid)

Figure 2.3 The Biosynthesis of Camitine .
Source: Leibovitz (1984). Camitine: How it functions in your body. In: Camitine: The
Vitamin B T Phenomena. pp. 24-38, Dell Publishing Co., Inc., New York.
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chain acyl residues accumulated in the peroxisomes, prevention of fatty liver development,
and detoxicification of drugs (refer to 73,76,77, 80, and 81 for complete review of the
above functions).

2.3.5 Carnitine and Drue;/Xenobiotic Interactions
Chronic consumption of ethanol is widely known to inhibit beta-oxidation which
leads to fatty infiltration in human and animal livers (10,12). Impaired oxidation and/or
increased lipogenesis are the suggested mechanisms of this malady ( 1 2). In addition,
ethanol depresses the activity of camitine palmitoyltransferase I, the rate limiting enzyme in
the transportation of long-chain fatty acids into the mitochondria (82). This inhibition may
also contribute to accumulation of fat in the liver. Supplementary carnitine has been
reported to inhibit this fatty liver phenomena caused by ethanol (13, 14, 1 5). Carnitine may
also offer protection against the toxicity of other alcohols such as methanol, isopropanol
and ethylene glycol (a common anti-freeze.) This is because carnitine prevents
accumulation of these alcohols by enhancing their excretion in the urine (83).
Carnitine may also alleviate the toxicity of adriamycin (doxorubicin hydrochloride), a
widely used anti-cancer drug. Adriamycin treatment has resulted in a series of acute and
chronic side-effects and cardiomyopathy in rats and humans and (quoted from 1 6,84). It
was found that carnitine administration decreased histophatological changes and
ameliorated irregular heart performance due to adriamycin ( 16,84). Furthermore, carnitine
lengthened the survival rate of mice following chronic adriamycin administration than the
mice that were administered with adriamycin only (85).
Valproic acid, a short chain fatty acid, is a frequently used anticonvulsant drug. This
drug has produced very serious side effects similar to Reye's syndrome (i.e. stupor,
hyperammonia, coma, and hepatic dysfunction) (86). Vaproic acid treatment in epileptics
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lowers the serum free carnitine but increases the short-chain acylcarnitine concentrations in
the patients (87 ,88). When vaproic acid was treated together with other drug such as
primodone, phenobarbital, ethosuximide or phenytoin, total camitine was markedly
reduced.
Lately, camitine has been found to conjugate with certain drugs/xenobiotics. For
example, vaproic, cycopropanecarboxylic (CPCA), and pivalic acid have been found to
conjugate with camitine and are then excreted in the urine by humans (quoted from 89).
Prolonged high doses of CPCA decrease free and total carnitine in the hearts of female rats.
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CHAPTER 3

MATERIALS AND METHODS

3, 1 ANIMALS AND HOUSING
Male Sprague-Dawley rats (Harlan, Indianapolis, ID) were used in this experiment.
They were acclimatized to the animal facility for 7 d upon arrival and had free access to
food and water. All rats were housed in individual wire-meshed bottom, suspended,
stainless steel cages in a cubicle of an AAALAC approved animal facility. The room
temperature was maintained at 23 ± 1 <>c, relative humidity around 45%, and with a 12-h
light/dark cycle.

3,2 DIETS
During the acclimatization period, the animals were fed Purina Rodent Chow pellets
#5001 (Ralston Purina Co., St Louis, MO). For the experiment, the diets were either
ground Purina Rodent Chow, or the same ground Purina Rodent Chow supplemented with
0.5% ( w/w) L-carnitine-HCI (Sigma Chemical Co., St Louis, MO) which contained about
0.4% L-carnitine. The diets and water were provided ad libitum .

3,3 EXPERIMENTAL DESIGN AND TREATMENTS
In Experiment 1 , twenty Sprague-Dawley rats were divided into 4 groups (b.w.
about 270-273 g) as shown in Table 3. 1. NSC and NSA groups consisted of the non-
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Table 3. 1 Desi gn of Experiment 1.
GROUPS l

NSC

NSA

csc

CSA

5

5

5

5

274
± 9.2

273
± 9. 8

0.5

0.5

# Animals
Body Weight,
( g ± SD)

27 1
± 11

270
± 13

L-Camitine.HCL
(%,w/w)
AFB 1
(mg/kg b.w.)
1 NSC = Nonsupplemented Control
NSA = Nonsupplemented Aflatoxin

1 .0

1 .0

CSC = Camitine-supplemented Control
CSA = Camitine-supplemented Aflatoxin
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carnitine supplemented rats and CSC and CSA were the carnitine-supplemented animals.
For Experiment 2, 1 0 rats were divided into 2 groups (Table 3.2). NSA group was fed
with the regular diet, while CSA group received the carnitine-supplemented diet. Bcxly
weights were monitored weekly.
After 6 weeks on the diet, a single oral dose of 1 mg/kg [3H]AFB 1 (Moravek
Biochemicals, Brea, CA) was administered by gavage to NSA and CSA groups in
Experiment 1 and to both groups in Experiment 2. Unlabelled AFB 1 (Sigma Chemical
Co., St. Louis, MO) was dissolved in methanol while the [3H]AFB 1 came already
dissolved in methanol. The cold AFB 1 was mixed with [3H]AFB 1 to get the spec. act. of
8 µCi/µmol. The above AFB 1 solution was dissolved in com oil to give a final
concentration of 1 .0073 mg of diluted [3H]AFB 1 in 1 ml of corn oil. NSC and CSC
groups were given 1 ml/kg suspension of methanol:corn oil ( 1 :9, v/v) by gavage.
Six hours in Experiment 1 and 24 h in Experiment 2 after the [3H]AFB 1
administration, the animals were anesthetized with mcthoxyflurane (Pitman-Moore, Inc.,
Washington Crossing, NJ) and blood samples were collected by cardiac puncture. The
animals were euthanized by exsanguination, and the livers and kidneys were removed. The
livers were rinsed with cold 0.9% NaCl to remove blood, blotted, dipped in liquid
nitrogen, weighed, and stored immediatedly at -70
liquid nitrogen, weighed and stored at -70 °c.

oe. The kidneys were also dipped into

3,4 TISSUE HOMOGENATE PREPARATIONS
Whole livers and kidneys were allowed to thaw. The livers were added to 1 volume
of cold 0.2M Tris buffer containing 1 . 1 5% KCl in a teflon glass homogenizer. The
kidneys were placed in a teflon glass homogeniz.er containing 2 volumes of the Tris buffer.
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Table 3.2 Design of Experiment 2.

NSA
# Animals
Body Weight,
(g ± SD)

GROUPS 1

CSA

5

5

338

336
±7

±8

0.5

L-Camitine.HCL
(%,w/w)

AFB t

1.0

(mg/kg b.w.)

1 NSA = Nonsupplemented Aflatoxin
CSA =-Carnitine-supplemented Aflatoxin

1 .0
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The tissues were homogenized by 6 complete strokes according to the method of Campbell
et al. (51). The livers and kidneys were rinsed with I volume of the buffer, vortexed and
each homogenate was placed into 7 separate 5 ml capacity culture tubes. The tissue
homogenate were prepared at 0-5 oC and stored at -70 oc. For analysis, only one tube of
each tissue homogenate was thawed and used for one assay. Thus, repeated thawing and
freezing were avoided and homogenate samples in different tubes were used for
determination of the tissue radioactivity, camitines, lipids, macromolecules, and AFB I macromolecules adducts.

3,5 BLOOD PLASMA PREPARATION
The blood samples collected by cardiac puncture were placed into heparin-containing
tubes ( 143 USP units of s�um heparin, Becton-Dickinson, Rutherford, New Jersey).
They were later centrifuged at 1500 x g at 4 oC for 10 min. The plasma was transferred
into culture tubes and stored at -70 oC. The plasma was analysed for all the assays as
carried out in the tissue homogenates except for the quantitation of macromolecules and
AFB I-macromolecules adducts.

3,6 ANALYTICAL PROCEDURES
3.6, 1 Tissue Radioactivity
The measurement of tissue radiuactivity was done following the method of Petroff et
al. (90). 100 µg of the tissues (livers or kidneys) was added with 2 ml 2N methanolic
KOH in scintillation vials. Joe tissues were digested at 70 oC in a water bath for 3 0 min,
cooled to room temperature, and 15 ml Aquasol-2 (NEN® Research Products, Boston,
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MA) was added to each tubes. Approximately 300 µl glacial acetic acid was added to
decrease the random coincidence monitor (RCM) to less than 5%. The radioactivity was
counted in a liquid scintillation counter (LS-380 1Beckman Instrument, Irving, CA.)

3.6,2 Carnitine
Tissue and plasma carnitines were detennined according to the radioisotopic method
of Cederblad and Lindstedt (9 1) as described by Sachan et al. ( 13). Three different
fractions of catnitine were measured, namely, free carnitine or non-esterified carnitine
(NEC), shon-chain acylcamitine or acid soluble acylcamitine (ASAC), and long chain
acylcarnitine or acid insoluble acylcarnitine (AIAC). Summation of these three fractions
gave the total carnitine (TC) of the tissue or plasma samples.
Perchloric acid was used to extract the ASAC, while potassium hydroxide and
heating were used to hydolyze and extract AIAC. The NEC was assayed by the addition of
carnitine acetyltransferase (CAT) and sodium tetrathionate which drove the following
reaction to the right by binding of CoASH.
14

�-Camitine + [ 1- C]Acetyl CoA

CAT > [ 1- 14 C]Acetyl Carnitine + CoASH

The reaction mixture was passed over an ion-exchange resin column where 1 - 14C
acetyl camitine was eluded and unreacted-labeled acetyl CoA was trapped. Scintillation
solution was added to the eluate and radioactivity was detennined in a Beckman scintillation
counter. Tissue carnitine was expressed in µmol/g wet wt of tissue, and plasma carnitine
as nmol/ml. The details of carnitine determination procedures used in Sachan's laboratory
( 13) are described as follows:
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3.6.2,a Rea�ents
1. 0.5 mM camitine standard solution (stock): 9.88 mg L-camitine HCL (Sigma
Chemical CO., St. Louis, MO) was dissolved in cold glass distilled water (GDW)
and diluted to 100 ml in a volumetric flask. This stock standard was diluted 1 :2
to give a working standard concentration of 0.25 mM.
2. 22.9 mM L-palmitoylcarnitine standard (stock): 1.0 ml of GDW was added to a
vial containing 10ml of L-palmityl carnitine (Sigma Chemical Co., St. Loius,
MO). This stock standard was diluted 1: 100 to give a working standard
concentration of 0.229 mM.
3 . Camitine standard mixture: Working standard were prepared by mixing equal
volumes of L-camitine and L-palmitoyl camitine.
4. 0.5 M Potassium hydroxide: 28.05 g of KOH was dissolved in some GDW and
diluted to a volume of 1 liter.
5. 4 M Potassium hydroxide: 56. 11 g of KOH was dissolved in some GDW and
diluted to a volume of 250 ml.
6. 0.6 M Perchloric acid (PCA): 5 1.26 ml of 70% PCA was added in some GDW
and diluted to a volume of 1 liter.
7. 0. 1 M Sodium tetrathionate: 0.6756 g of anhydrous sodium tetrathionate (J.T.
Baker Chem. Co., Phillipsburg, NJ) was dissolved in GDW and diluted to a
volume of 25 ml.
8. 0. 1 % Phenol red: 100 mg of phenol red (Sigma Chemical Co., St. Laius, MO)
was dissolved in absolute ethanol and made to a volume of 100ml. Phenol red
tubes were prepared by adding one drop of phenol red to 12 x 75 mm Pyrex
glass tubes and allowed to dry.
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9. [ I- 14C] acetyl Coenzyme A: 50 µCi of [ I- 14C] acetyl Coenzyme A (Amerstam
Corp., Chicago, IL) was dissolved in cold GDW and made to a volume of 3 00
ml. 5.0 ml aliquots were dispensed into plastic vials and frozen at -70 oc.
1 0. IM Potassium bicarbonate: 1 g potassium bicarbonate (Certified ASC, Fisher
Scientific Co., Fair Lawn, NJ) was dissolved and made to a volume of 1 0 ml
with GDW. Solution was stored at room temperature and made daily.
11. 0. 1 M acetic anhydride: 0.5 ml of acetic anhydride (Fisher Scientific Co., Fair
�wn, NJ) was added to 4.95 ml of cold GDW and used immediatedly for acetyl
CoA solution.
12. 0. 1 mM acetyl Coenzyme A: 1 0 mg of acctyl Coenzymc A (Sigma Chemical Co.,
St. Louis, MO) was added to 0.5 ml cold GDW and mixed. Then, 100 µl of 1 M
potassium bicarbonate was added and mixed, and followed by the addition of 200
µI of 0. 1 M acetic anhydride. The solution was made up to 80 ml with cold
GDW, mixed thoroughly, and dispensed into plastic vials and frozen at -70 °C.
13 . Carnitine acetyltransferase (CAT): CAT from pigeon breast muscle (Sigma
Chemical Co., St. Louis, MO) was diluted with GDW to give an enzyme activity
of. 50 units/ml.
14. 1 M (3 -(4-morpholino)propanesulfonic acid] MOPS: 20.92 g of MOPS (Sigma ·
Chemical Co., St. Louis, MO) was added to about 80 ml of GDW. The pH was
adjusted 7.4 with 4 M potassium hydroxide and was diluted to a volume of 100ml
with GDW.
15. PCA/MOPS-1: 20.9 g of MOPS was added to 50 ml of 0.6 M PCA and brought
up to a volume of 100 ml with GDW. The solution was stored at 4 °C.
16. PCA/MOPS -II: 20.9 g of MOPS was added to 20 ml of 0.6 M PCA and
brought up to a volume of 100 ml with GDW. The solution was stored at 4 oC.
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17. 0. 1 M ethylene glycol-bis (beta-amino-ethylether) N, N-tetraacetic (EGTA), pH 7:
1.902 g EGTA (Sigma Chemical Co. , St. Louis, MO) was added in 3 0 ml GDW,
adjusted to pH 7 .0 with 4 M potassium hydroxide, and diluted to 50 ml with
GDW.
18. 0. 1 mM [ 1- 14C] acetyl Coenzyme A solution: 2: 1 volumes of (l- 14C] acetyl CoA
and 0. 1 mM acetyl CoA were mixed and stored at 4 oC.
19. Reagent mixture for one assay: 1 M MOPS, pH 7.4, 120 µl; 0. 1 M EGTA, pH
7.0, 20 µl; 0. 1 M sodiu� tt:trathionate, 20 µ1; 0. 1 mM [ 1- 14C]-acetyl CoA
solution, 200 µI; .GOW, 40 µI; to a volume of 400 µI.
20. 8% bovine serum albumin (BSA): 4 g of BSA (Fatty acid poor, Fraction V, ICN
Pharmaceuticals Inc. , Life Sci. Group, Cleveland, OH) was dusted into about 20
ml of GDW, stirred gently, and diluted to 50 ml.
2 1. Scintillation fluid: Ready-Solv® CP (Beckman Instruments, Palo Alto, CA).

3,6,2,b Procedure
Aliqouts of 200 µI of tissue homogenates and blood serum were placed in 200 µI of
PCA in a 12 x 75 mm Pyrex glass test tubes. The contents were vortexed thoroughly and
centrifuged (Model TJ-6, Beckman Instruments, Palo Alto, CA) at 1 500 x g for 10 minutes
at 4 oc. Nonesterified camitine (NEC) and acid soluble acylcamitine (ASAC) were
contained in the supernatant, while the acid insoluble camitine (AIAC) was contained in the
pellet.
Camitine standards were made by adding 1 0, 20, 3 0, 40, and 60 µl of carnitine
standard mixture to 200 µI of PCA in 12 x 75 mm Pyrex glass test tubes (Refer to Table
3 .3 ). Blank was made by mixing 100 µl of GDW, 100 µI of BSA, and 200 µ of PCA .
The standards and blank underwent the same procedures as in the samples.

Table 3.3 Carnitine Standard Preparations.

0.25 mM
Carnitine

0.23 mM
P-Carnitine 1

-------··-------------------------

GDw2

8% BSA3 6% PCA4

Total

Total Camitine

(nm)

(µI)

(µI)

(µI)

(µl)

(nm)

0

0

100

100

200

400

0

1 .25

5

1.15

90

100

200

400

2.40

10

2.50

10

2.30

80

100

200

400

4.80

15

3.75

15

3.45

70

100

200

400

7.20

20

5.00

20

4.60

60

100

200

400

9.60

30

7.50

30

6.90

40

100

200

400

14.40

(µI)

(nm)

(µl)

0

0

5

I L-Palmityl Carnitine

2Glass distilled water
3Bovine serum albumin
4 Perchloric acid
w
.J::.
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150 µI and 100 µI of the supernatant from the tissue samples, blood, blank and
standards were transferred to 12 x 75 mm phenol red tubes that were labeled NEC and
ASAC respectively. The pellets were drained of the supernatant by inverting the tubes.
Nonesrerified Camitine Detennination

35 µl of 1 M potassium bicarbonate was added to the 150 µI of the supernatant in the
phenol red test tube and vonexed. The contents were slightly acidic as indicated by a
golden yellow color. The mixtures were held for 3 0 min on ice.

Acid Soluble Acylcarnitine Detennination
75 µI of 0.5 M potassium hydroxide was added to the 100 µl of the supernatant in
the phenol red test tube and vonexed. The contents were slightly alkaline as indicated by a
purple-red color which was essential for hydrolysis. The contents were incubat� in a 3 7
oc rotating water bath ( 100 shakes/min) for 3 0 min for complete hydrolysis. The mixtures
were then neutralized by adding 3 0 µl of PCA/MOPS-11, and vonexed. They were held on
ice for 3 0 min.

Acid Insoluble Acylcamirine Detenninarion
The pellet was washed twice with 200 µI of 0.6 M PCA and the washes were
drained by inverting the tube. One drop of phenol red indicator and 200 µl of 0.5 M
potassium hydroxide were added to the tube and vonexed vigorously for several min until
the pellet was completely dissolved. The contents were alkaline indicated by purple-red
color and were hydrolyzed in a 65 oC shaking water bath (100 spm) for 60 min. Then,
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1 00 µI of PCA/MOPS-I was added and vortexed to neutralize the contents. They were held
on ice for 3 0 min.

3,6.2.c Assay for Camitine

The NE C, ASAC, and AIAC tubes were centrifuged at 1500 x g at 4 °c for 1 0 min.

A 100 µI aliqout was transferred from each of the fractions to 1.5 ml microfuge tubes
separately. Four hundred µI of reagent mixture were added followed by 20 µI of carnitine
acetyltransferase (CAn. The tubes were capped, mixed by gentled tapping, incubated in a
3 7 oC shaking water bath for3 0 min. Later, 200 µI of the incubated mixture was
transferred onto a mini column, and the elutant was collected into plastic mini scintillation
vial (Beckman Instrument, Palo Alto, CA). The mini columns were made by stuffing the
area above 5-3 /4" Pasteur pipettes (Fisher Scientific Co., Fair Lawn, NJ) with glass wool.
Anion Exchange Resin, AG I-X8, 200-400 mesh, Cl-form (Bio-Rad Laboratories,
Richmond, CA) was added up to the 9 cm mark measured from the tip of the pipette.
When the 100 µl aliqout was fully absorbed, the column was washed with 2 portions of
500 µI GOW, and the washes were also collected into the same respective scintillation vial.
Then, 5 ml of scintillation fluid was added to each vial, capped, mixed by swirling, and
counted for 10 min/vial in a scintillation counter (LS-3 80 1 Beckman Instruments, Irving,
CA).
Dual radioactivity counts were employed to determined the amount and AFB 1
conjugation to each of the carnitine fractions (refer to Appendix A-3 . 1 for the procedures �f
dual radioactivity counts as described in the Beckman Liquid Scintillation Systems
Operating Manual, Beckman Instruments, Irving, CA.) The disintegration per minute
(DPM) for the NEC, ASAC,and AIAC, and their standards were adjusted by substracting
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the blank's DPM. Standard curves for the camitine fractions were plotted as shown in
Figure 3. 1 and 3.2. The calculation for camitine concentrations were as follows:

D •F . = umoles carnitine
g tissues

Liver :

DPM

Blood serum:

DPM x I.S. x D.F. = nmoles carn itine
ml serum

where :

X

I• S •

X

DPM = Disintergration per min
I.S .

= Inverse slope

D.F. = Dilution factor (appropriate to bring the amount of camitine
to 1 g or 1 ml)

3.6.3 Total Lipids
Total lipids concentrations of the liver, kidn�y, and plasma were determined
according to the phosphoric acid-vanillin reaction method of Ellenston and Caraway (92).
The principle of this method is that unsaturated fatty acids are oxidised to form ketones that
react with phosphovanillin to yield a pink-colored product.

3,6,3.a Rea�ents
1 . Sulfuric acid (AR).
2. Phosphoric acid-vanillin reagent: 1 g of vanillin (Sigma Chemical Co., St.
Louis, MO) was added to 1 60 ml of GDW, and brought up to a volume of 500
ml with phosphoric acid
3. Stock standard : 1 g of olive oil was placed and mixed in a 1 00 ml volumetric
flask containing some chloroform. The volume was brought up to the volume
with chloroform, mixed thoroughly, and stored at -20 oC.
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4. Working standard: 1 ml of the stock standard was placed in a 10 ml volumetric
flask, brought up to the mark with chloroform, and stored at -20

°c.

3,63,b Procedure
Tissue homogenates ( 1 : 8 w/v) and blood serum (0.2 ml) were transferred to
different 1 6 x 1 50 mm glass test tubes, while 0.2 ml GOW was placed for blank. For the
I

standards, 0.05, 0. 1 , and 0.2 ml of the working standard solution were placed into
separate tubes. The chloroform in the standards was evaporated off with a stream of
nitrogen, and 0.2 ml GOW was added and 5 ml concentrated sulfuric acid were added to all
tubes and vortexed. The tubes were stopped and heated at 1 00 oC for 1 0 min in a heating
block (Precision, GCA Corp.). The tubes were cooled to room temperature. Two hundred
µl of the contents of each tube was transfered to 12 x 75 mm test tubes and 3.0 ml
phosphoric acid-vanillin reagent was added and mixed The tubes were allowed to stand
for 60 min in darkness. Absorbances were read at 520 nm in a Beckman spectrophometer.
The standard curve is shown in Figure 3.3. The concentrations were calculated as follows:

Total lipids (mg/g tissue or mg/ml serum) = Abs. x Slope x D.F.
where;

Abs. = Corrected absorbance of sample
D.F. = Dilution factor

3.6,4 Tri�lycerides
Triglyceride contents were measured according to the procedure of Geigel et al. (93).
The principal of this method is that triglycerides are extracted from the samples by an
extraction reagent (nonane). Phospholipids or other interfering components are left
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unextracted. The extracted triglycerides are hydrolyzed by sodium hydroxide and heating.
The liberated glycerol is then oxidized by sodium periodate to form formaldehyde which
condenses with ammonia and acetylacetone to foim yellow diacetyldihydrolutict:ic which
can be measured at 4 1 5 nm.

3.6,4.a Rea�ents
1 . Extraction reagent: n-nonane/isoproponal (2.0/3.5, v/v).
2. Triolein standard : 1 00 mg triolein (Sigma Chemical Co., St. Louis, MO) in 1 00
ml extraction reagent ( 1 . 1 3 mM).
3. Dilute sulfuric acid, 40 mM.
4. Transesterifying reagent: sodium hydroxide in isopropanol ( 1 OOmM/1).
5. Oxidizing reagent:· sodium periodate ( 1 8 mM) in 2 M acetic acid.
6. Color buffer: ammonium acetate (6.0 M, pH 6.0 at 25 oC).
7. Working color reagent: 4.0 ml of acetylacetone mixed with 1 00 ml of the color
buffer, and let stand for more than 1 5 min before use.

3.6,4,b Procedure
Aliquots of plasma and tissue homogenates (0.2 ml each) were transfered to separate
1 6 x 100 mm screw-capped test tubes containing 5.0 ml extraction reagent. Then, 1 .0 ml
dilute sulfuric acid was added. A blank and standards were made by adding 0, 0. 1 , 0.2,
0.4, and 0.6 ml of triolein standard and diluted to 5.0 ml with extraction reagent. All the
tubes were cennifuged at 1 500 x g at 4

°c for 1 0 min. Later, 0.5 ml aliquot of each upper

phase was added to 0.5 ml of transesterifying reagent, held at room temperature for 5 min,
mixed with 0.5 ml of oxidizing reagent, and held again at room temperature for 5 min.
After the two-phase fraction had developed, 6 ml of the working color reagent was added
to each tube and incubated at 60

°c for 1 0 min.

The tubes were cooled to room
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temperature and the absorbance of the standards and samples was read against the blank at
4 1 5 run. See Figure 3.4 for triglycerides standard curve. The calculations were as
follows:

Triglycerides (mg/di) = Abs. x I .S. ·X D.F.

where:

Abs.

= Absorbance of unknown

I.S .

= Inverse slope

D.F.

= Dilution factor

3.6.5 Macromolecules and AfB1-Macromoiecule Adducts Ouantitation
The extraction and isolation of macromolecules namedly RNA, DNA and protein,
were done following the procedure of Glazer et al. (94). Perchloric acid (PCA) was used
to precipitate .the macromolecules. The pellet was treated with potassium acetate,
chloroform:ethanol, and absolute ethanol to remove lipids. The pellet was resuspended
with PCA and left overnight. The supernatant contained t!1e RNA fraction. To isolate the
DNA and protein, PCA was added to the pellet and heated. The supernatant contained the
DNA fraction. Potassium hydroxide was added to the rest of the pellet and heated to get
the protein fraction.

3,6,5,a Reaeents
1 . 0.2N, 0.5N, I .ON, and 1 .5N PCA from 70% PCA.
2. 0. 1 N potassium acetate (KAc) in absolute ethanol.
3. Chloroform:absolute ethanol (l : l , v/v).
4. 1 .0 N potassium hydroxide (KOH).
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5. 0.04 % indole.
6. Concentrated HCI.
7. Chloroform.
8. Alkaline Copper Sulfate Solution prepared daily by adding 50 ml of O. l N NaOH
containing 1 g sodium carbonate, 0.5 ml of 2 % (w/v) sodium-potassium
tartarate, and 0.5 ml of 1 % (w/v) cupric sulfate.
9. Phenol Reagent (Sigma Chemical Co., St Louis, MO).

3.6.5.b Standard Solutions
The standard solutions were prepared as shown in Table 3 .4. Ten ml of calf
thymus DNA (4.0 mg/ml), yeast RNA (8.0 mg/ml) and bovine serum albumin (BSA) for
protein (50 mg/ml) were prepared in three different tubes for stock standard solutions.
Aliquotes of these stock solutions were dispensed into 4 different tubes such that different
concentrations of the DNA, RNA, and protein were mixed together in one tube for each set
of working standards. For example, in Standard 1, the tube contained 0.25 mg of DNA,
0.5 mg of RNA, and 10 mg of protein in a total of 5 ml of working standard solution.

3.6.5,c Extraction and Isolation
Aliquotes of 0.4 ml of the 1 : 8 (w/v) liver homogenate (50 mg tissue) and the
working standard solutions were added to ice-cold I .ON PCA, vortexed, and centrifuged at
2700 x g for 1 5 min at 2 o c. For blank, 0.4 ml GDW was added to the blank tube. The
supernatant was discarded. The pellet was washed and centrifuged 4 times with 1 . 5 ml
0.2N PCA. The supernatant was removed each time. Lipids were removed by treating the
pellet once with 1 .5 ml of 0. l N KAc in absolute ethanol, twice with 1 .0 ml of
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Table 3.4 Preparation of Macromolecule Standard Solutions.
Standard
Tubes #

DNA
(4 mg/ml)

RNA
(8 mg/ml)

Protein
(50 mg/ml)

---------------- µ! (mg)---------------

aowl

Total Volume

ml

ml

1

62.5 (0.25)

62.5 (0.5)

200 (10)

4. 675

5

2

125 (0.50)

125 ( 1 .0)

400 (20)

4. 350

5

3

250 ( 1 .00)

250 (2.0)

800 (40)

3.700

5

4

375 ( 1 .50)

375 (3 .0)

1 600 (80)

2.650

5

lGiass Distilled Water
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chlorofonn:absolute ethanol and once with 1 .0 ml of absolute ethanol. During each
treatment, the tubes were vortexed, centrifuged, and supernatant was drained completely
(especially the last step). The precipitate was resuspended with 1 .0 ml of 1.5N PCA,
vortexed, and left overnight in the refrigerator (4 oc for about 1 8 h). The next day, the
tubes were centrifuged and supernatant was collected The precipitate was washed twice
with 0.5 ml of 0.5N PCA, vortexed, centtifuged, and the supernatant was collected each
time. The combined supernatant contained the RNA fraction. The pellet was then added to
1 .0 ml of 0.5N PCA, vortexed, and incubated in. a .70 oc water bath for 20 min,
centrifuged, and the supernatant collected This was repeated twice and the combined
supernatant contained the DNA fraction. The precipitate was dissolved in 1 ml 1 .0N KOH,
vortexed, and incubated at 70 <>c for 15 min and centrifuged The supernatant contained
the protein fraction. RNA was determined on the same day, while DNA and protein were
stored at -70 oC until analyzed

3.6,5.d Detennination
RN A was measured spectrophometrically against the blank at 260 nm using UV light
(94). DNA was determined colorimetrically by the method of Ceriotti (95). One ml of the
DNA extract was added with 0.5 ml of 0.04% cold indole and 0.5 ml concentrated HCI.
The tubes were vortexed and heated in a 100 <>c water bath for exactly 10 min. The tubes
were cooled under running water. The water layer (top layer) was extracted twice with 2
ml chloroform and centrifuged each time. The lower layer (chloroform layer) was removed
using a clean Pasteur pipette each time. The samples were read at 490 run against the
blank.
Protein determination was carried out as described by Lowry et al. (96). 0.2 ml of
the KOH protein solution was removed and marked-up to 1 ml with GDW in a 10 ml tube.
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Six ml of the alkaline copper sulfate solution was added, vortexed, and left to stand for 5
min at room temperature. Then 0. 3 ml of phenol reagent was added, vortexed
immediately, and left at room temperature for at least 30 min. The tubes were centrifuged
for 5 min and the absorbance were read at 650 nm against the blank.
The standard curves were drawn for each of the macromolecules (Figures 3 .5, 3 .6,
and 3.7.) The concentrations were calculated as follows:
DNA/RNA/PROTEIN (mg/g liver) = ABS. x inverse slope x D.F.
Where,

ABS. = Corrected absorbance of sample
D.F. = Dilution factor

3.6.5,e r.lHJAFB,1-Macromolecules Adducts
RNA, DNA, and protein extracts (0.5 ml each) were dispensed into separate 20 ml
scintillation vials. Fifteen ml of Aquasol-2 was added to the vials and mixed For protein,
100 µI of glacial acetic acid was added. The radioactivity was counted in a Beckman liquid
scintillation counter for 10 min. The disintergration per minute (DPM) was calculated as
follows:
DPM/mg RNA, DNA, or protein = DPM/0.5 ml sample x D.F.
Where,

D.F. = Dilution factor

3.7 PRECAUTIONARY AND DECONTAMINATION PROCEDURES
The safety and decontamination procedures followed during handling of AFB 1 were
as recommended by Stoloff et al. (97), Fischbach et al. (98), and Castegnaro et al. (99).
Briefly, when handling the AFB 1 , disposable rubber gloves, face mask and lab coat were
always worn. Dry or concentrated toxins from the manufacturer were handled under the
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hood. To decontaminate any spillage, 5% sodium hypochlorite (full strength regular
household bleach} was used to wet or soak the contaminated surface for at least 30 sec.
The surface was then wiped with paper towels. Before washing contaminated laboratory
wares, they were soaked for at least 30 sec with diluted bleach (0.5% NaOCl}. Refer to
Appendix A-3 .2 for the complete details of the procedures.

3,8 STATISTICS
All values are expressed as group mean ± standard error of mean. Two-way crossed
ANOVA were used when data from 4 experimental groups were analyzed and compared,
and when significant, Duncan's New Multiple Range Test was used. When analyzing and
comparing data from 2 experimental groups, Student's t-test was used. The minimal level
of significance accepted was p S 0.05.
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CHAPTER 4
RES ULTS
The effect of camitine supplemented diet and/or AFB 1 treatment on the rats body
weight and organ weight are summarized in Tables 4. 1 and 4.2. Carnitine supplemention
had no significant effect on weight gain or liver and kidney weights. AFB 1 treatment too
had no effect on organ weights. The 24-hour urinary output and amount of AFB 1 excreted
in the urine were not affected by AFB 1 treatment in both the NSA and CSA groups (Table
4.3). Even though it is not significant, the CSA group had slightly larger percentage of
AFB 1 dose (58. 1 1 %) excreted in the urine than in the NSA group (54. 1 6 % ) .
The results of the effects of camitine supplemented diet and AFB 1 treatment in
Experiment 1 are presented in Table 4.4. In the AFB 1 treated rats, the amount of total
lipids in the liver was significantly lower in the camitine supplemented groups, CSC (59.3
mg/g) and CSA (59.5 mg/g), compared to the NSA group (65.3 mg/g). The liver
triglyceride concentrations was lower in the CSC group than the other three groups.
Carnitine and AFB 1 treatments did not change the amount of total lipid in the kidney . In
the plasma, the diet x · AFB 1 interaction significantly affected the total lipid and triglyceride
content indicating that in non-supplemented groups, AFB 1 treatment lowers the
concentration of the total lipids and triglycerides. In contrast, in the camitine-supplemented
groups, AFB 1 treatment increased the concentrations of the total lipid and triglyceride in the
plasma. CSC group had lower amount of total lipids (20% lower) and triglycerides (37.2
% lower) content in the plasma than the NSC group. The percent differences in the total
lipid and triglyceride contents are shown in Appendex A-4. 1.

Table 4. 1 Effects of Camitine Supplemented Diet on Body, Liver and Kidney Weights
of Rats in Experiment 1 (6 h Post-AFB 1 ).
Groups l
NSC

csc

NSA

CSA

Initial Body Weight (g)

27 1 .0 ± 5.02

270.4 ± 5.9

273.5 ± 4. 1

272.3 + 4.5

Final Body Weight (g)

395.5 ± 1 3.6

393.0 ± 13.9

398.5 ± 7.4

394.3 ± 8.0

Weight Gain (g)

124.5 ± 8.7

122.6 ± 8.6

124.9 ± 4.6

122.0 ± 1 1 .4

Liver Weight (g)

1 3.6 ± 0.6

1 3.2 ± 0.5

12.9 ± 0.3

13.4 ± 0.7

Liver/Final Body Weight (%)

3.4 ± 0.09

3.3 ± 0.08

3.2 ± 0.07

3.4 ± 0. 1 5

Kidney Weight (g)

2.6 ± 0.09

2.5 ± 0. 13

2.6 ± 0.05

2.5 ± 0.05

0.66 ± 0.0 1

0.63 ± 0.02

0.64 ± 0.01

0.64 ± 0.02

Kidney/Final Body Weight (%)

1 NSC = Nonsupplernented Control; N SA = Nonsupplemented AFB I; CSC = Camitine S�pplemented; CSA = Carnitine
S upplernent AFB } .
2The values are mean ± SEM (n = 5). All values are not statistically different (p � 0.05).
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Table 4. 2 Effects of Carnitine Supplemented Diet on Body, Liver and Kidney Weights of
Rats in Experiment 2 (24 h Post-AFB 1 ).
Groups l
NSA
Initial Body Weight (g)
Final Body Weight (g)

± 3.72
403.2 ± 6.3
338.5

CSA
336. 1

± 3.3

40 1 . 8

± 2.7

Weight Gain (g)

64.7

± 4.0

65.7

± 2.6

Liver Weight (g)

1 1 .6 ± 0.3

1 2.0

± 0.2

2.9 ± 0.05

3.0

± 0.06

± 0.06
0.61 ± 0.0 1

2.4

± 0.05

Liver/Final Body Weight (%)
Kidney Weight (g)
Kidney/Final Body Weight (%)

l NSA

2.5

0. 59 ± 0.0 1

= Nonsupplemented AFB 1 ; CSA = Carnitine Supplement AFB 1 .

2The values are mean ± SEM (n = 5). All values are not statistically different (p � 0.05).
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Table 4.3 Effects of Supplementary Camitine on AFB 1 Urinary Excretion
in Rats of Experiment 2 (24 h Post-AFB t).

Groups l
NSA

Amount of Urine
(ml/24 h)

2 1.05 ± 4.05 2a

Total Amount of [3HJA.FB 1 Excreted
(µg AFB 1 in 24 h)
223.99 ± 34.85 a

Dose in Urine
(% )

54. 16 ± 7.88

Amount of [3H]AFB 1 Excreted/ml Urine
1 .40 ± 0. 1 8a
(µg AFB 1 /ml Urine)

l NSA

CSA

% Different

18. 10 ± 2.02 a

1 4.0

235 . 17 ± 15.02 a

5.0

58. 1 1 ± 3.74

7.3

1 .56 ± o. 1s a

= Nonsupplemented AFB 1 ; CSA = Carnitine Supplemented AFB 1 .

2Toe values are mean ± SEM (n = 4 ). Values with different superscript letter are
significant (p � 0.05).

1 1 .4

Table 4.4 Effects of Diet and AFB 1 on Total Lipid and Triglyceride Contents
in Rats of Experiment 1 (6 h Post-AFB 1 ).
Groups l
NSC

NSA

csc

Liver:
Total Lipids (mg/g)2
Triglycerides (mg/g)

60.5 ± l . 6abx
23.5 ± 1 .3 ax

65.3 ± 2. 1 ax
27.9 ± o.5 ax

59.3 + 4. 1 b x
24.4 ± 1.2 ay

59.5 ± o.5bx
26. 1 ± o.1 ax y

Kidney:
Total Lipids (mg/g)
Triglycerides (mg/g)

28.3 ± 2.2ax
22.3 ± o.1 ax

29.9 ± 2.5 ax
24.0 ± o. s ax

28. 1 ± 1 . 1 ax
22.3 + 1 .oax

28. 1 + o.5 ax
22.6 ± 1 . 1 ax

Plasma:
Total Lipids (mg/di)
Triglycerides ( mg/di}

339. 1 ± 10.3 ax
82.2 ± 4.4ax

280.5 ± 34_3ax
57. 1 ± 4_9 ax

269 J ± 26. 4aX
5 1 .6 ± 10.1 ax

317.5 ± 25.2 ax
76.5 ± 13.4ax

CSA

1 NSC == Nonsupplemented Control; NSA = Nonsupplemented AFB 1; CSC = Carnitine Supplemented; CSA = Carnitine
Supplement AFB 1 .
2The values are mean ± SEM (n = 5 for liver and kidney; n = 4 for plasma). Those values in a line bearing the different superscript
letter (a - c) are statistically different (p � 0.05) due to diet treatment, and those bearing different superscript letters (x - z) are
significantly different (p �0.05) due to AFB 1 by a two-way crossed ANOV A. Diet x AFB 1 interaction was significant only in
plasma's total lipids and triglycerides (p � 0.05).
LIi
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S itnilar results for lipid were observed in Experiment 2 where the animals were
sacrificed 24 h after the administration of AFB 1 (Table 4.5). Liver total lipid and
triglyceride contents were statistically lower in the CSA group than in the NSA group. In
the plasma, the reverse was seen, i.e., NSA group had lower while CSA group had higher
amount of total lipids and triglycerides. The triglyceride concentration in the CSA group
was 1 5 .5% higher than in the NSA group and the difference was highly significant (p S
0.0 1 ). There were no differences in kidney lipids of the two groups.
Tables 4.6 to 4. 1 1 show the effects of carnitine and AFB 1 treatments on liver and
plasma camitine concentrations and the [ 3 H]AFB 1 radioactivities associated with them.
Camitine supplementation did not significantly affect liver camitine concentrations,
although all the carnitine fractions were higher in the CSC group as compared to the NSA
group (Table 4.6). However, AFB 1 treatment increased the NEC contents in both NSA
and CSA groups when compared to their respective control groups (NS C and CSC).
Camitine and AFB 1 treatments both elevated ASAC concentrations in the NSA and CSA
animals as compared to their respective control animals. The amounts of ASAC in the CSA
rats were significantly higher ( 1 9 1 .25 nmol/g) than in the NSA rats ( 1 1 5. 33 nmoVg). The
concentrations of AIAC were not significantly affected by the diet and AFB 1 treannents
eventhough there was about 50% increase compared to respective controls. The total
camitine contents were higher in both NSA and CSA groups when compared to their
control groups. The diet x AFB 1 interactions were not significant in all .the groups to affect
the concentrations of all the camitine fractions in the liver.
[ 3 H]AFB 1 radioactivity was only found in the AIAC fraction and is presented in
Table 4.7. Though it was not statistically significant, CSA group had 26.2% higher
amount of AIAC than the NSA groups per g liver. The amount of AFB 1 dose and
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Table 4.5 Effects of Diet and AFB 1 on Total Lipid and Triglyceride
Contents in Rats of Experiment 2 (24 h Post-AFB 1 ).
Groups l

NSA
Liver.

CSA

± 1.4a

Total Lipids2 (mg/g)

59. 8

Triglycerides (mg/g)

2 1 .7 + 0.5 a

Kidney:
Total Lipids (mg/g)
Triglycerides (mg/g)
Plasma:
Total Lipids (mg/ell)
Triglycerides (mg/dl)

l NSA

± 0.6a
1 8.2 ± 0.4a

28.8

±
59.5 ±

359.5

8.4a
3.9 a

% Different

± o.5 b

7 .7

19.0 + 0.4b

1 2.4

± 0.6a

0.7

17.9 + 0.7 a

1 .6

55.2

29.0

±
68.7 ±

396. 8

8.2b

1 0.4

2.6C

1 5. 5

= Nonsupplemented AFB 1 ; CSA = Carnitine Supplemented AFB 1 .

2Toe v�ues are mean ± SEM (n = 5 ) . bSignificant at p s; 0.05; CSignificant at p �0.01 .
Values with same superscript are not significant (p � 0.05).

Table 4.6 Effects of Diet and AFB 1 on Liver Carnitines (nmoVg) in
Rats of E xperiment 1 (6 h Post -AFB 1 ).
Groups l

Carnitine Fractions

--�

NSC

NSA

224.73 ± 9 .s3 2ax

398. 19 ± 33.69ay z

Acid-Soluble Acylcarnitine
(ASAC)

45.88 ± 9.55 a X

1 1 5.33 ± 11.07aby

Acid-Insoluble Acylcarnitine
(AIAC)

13.46 ± 3.25 ax

1 9. 16 + 2.1oax

Nonesterified Carnitine
(NEC)

Total Camitine

284.08 ± 1 2.41 ax

531.69 + 50.6sabcx

�

� -

csc
3 1 9.98 ± 4 1 .7 1 axz

98.04 ± 20.33ab x y

CSA
456.34 + 55.92ay

191 .25 ± 3 1 .23C Z

1 5. 10 ± 3.38aX

24. 19 ± 6.01 a x

433. 12 ± 59.22ac x

67 1 .79 + 9.53bX

1 NSC = Nonsupplemented Control; NSA = Nonsupplemented AFB I; CSC = Cami tine Supplemented; CSA = Carnitine S upplement
AFB 1 .
2Toe values are mean ± SEM (n = 5 ). Those values in a line bearing the different superscript letters a-c are statistically different (p �
0.05) due to diet treatment, and those values in a line bearing a suprscript letters x- z are statistically different (p � 0.05) due to AFB 1
treatment by a two-way crossed ANOVA. AFB I treatment and AFB I x diet interaction was not significant (p2:: 0.05).
UI
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Table 4.7 [3H]AFB 1 Binding to Liver Acid Insoluble Acylcarnitine (AIAC)
in Rats of Experiment 1 (6 h Post-[ 3 H]AFB 1 ).

Groups !
NSA
Amount of AIAC
(nmol/g liver)

1 9. 1 6 ± 2.102 a

Amount of dose in AIAC
(% Dose/pmol AIAC)

% Different

24. 1 9 ± 6.01 a

26.25

± 0.03 a

0.22 ± 0.01 a

4.76

3.64 ± 0.21 a

3.89 ± 0.32 a

6.87

1 6.60 ± 2.94a

1 7.50 ± 5.77 a

5.42

[ 3 H]AFB 1 -AIAC adducts/nmol AIAC
(nmol AFB 1/nmol AIAC)
0.2 1
[ 3H]AFB 1 in AIAC/g liver
(nmol AFB 1/g liver)

CSA

lNSA = Nonsupplemented AFB 1 ; CSA = Carnitine Supplemented AFB 1 .
2Toe values are mean ± SEM (n = 5 ). Values with different superscript letter are
significant (p S 0.05).
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Table 4.8 Liver Camitine Contents and [ 3H]AFB 1 -Acid Insoluble Acylcamitine Binding
in Rats of Experiment 2 (24 h Post-[3 H]AFB 1 ).
Groups l
NSA
Nonesterified Camitine (NEC)
(nmoVg liver)

438.22 ± 21.03 2 a

CSA

% Different

608.42 ± 36.63 b

38. 84

Acid Soluble Acylcamitine (ASAC)
261 .90 ± 35 .66a
(nmoVg liver)

190.96 ± 26.04 a

, 27.09

Acid Insoluble Acylcamitine (AIAC)
18.79 ± 5.61 a
(nmoVg -liver)

14.35 ± 3.99 a

23 .63

749.46 ± 57.99 a

834.53 ± 63. 19a

1 1 . 35

[ 3 H]AFB 1-AIAC adducts
(pmol AFB 1/nmol AIAC)

6.47 ± 2.04a

4.82 ± 1.24a

25.50

. [ 3 H]AFB 1 in AIAC/g liver
(pmol AFB 1/g liver)

84.71 ± 10.45 a

101 .22 ± 9 .3o a

19.49

Amount of dose in AIAC
(% Dose/pmol AIAC)

0.50 ± 0. 14a

0.37 ± o.os a

26.00

Total Camitine
(nmoVg liver)

l NSA

= Nonsupplemented AFB 1 ; CSA = Carnitine Supplemented AFB 1 .

2Toe values are mean ± SEM (n = 5 ). Values with different superscript letter are
significant (p � 0.05).

Table 4.9 Effects of Diet and AFB 1 on Plasma Camitines (µmoVml) in Rats
of Experiment 1 (6 h Post-AFB 1 ).

Camitine Fractions

Oroupsl

NSC

NSA

csc

CSA

Nonesterified Camitine
(NEC)

51 .02 ± o.47 2 bcd

43.82 ±1 .49d

74.65 + 7.53a

69.98 ± 9.41 ac

Acid-Soluble Acylcarnitine
(ASAC)

1 1 .91 ± 0.33 a

10.99 ± 0.5oa

10.72 ± 2.8oa

1 1 .53 ± 2.58 a

4.47 ± o.35 bc

3.56 + 0.22 b

6.33 ± o.soa

5.36 ± 0.61 ac

66. 15 ± t .64acd

57 . 80 ± 2.44 bd

91 .70 ± 10.78 a

90. 80 ± 1 1 .29ac

Acid-Insoluble Acylcamitine
(AIAC)
Total Camitine

2NSC = Nonsupplemented Control; NSA = Nonsupplemented AFB I ; CSC = Carnitine Supplemented; CSA = Carnitine Supplement
AFB 1 .
3Tue values are mean ± SEM (n = 5 ). Those values in a line bearing the different superscript letter are statistically different (p � 0.05)
due to diet treatment (p � 0.05) by a two-way crossed ANO VA. AFB t treatment and AFB t x diet interaction was not significant (p�
0.05).
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Table 4. 1 0 [3 H]AFB 1 Binding to Plasma Acid Insoluble Acylcarnitine (AIAC)
in Rats of Experiment 1 (6 h Post-[ 3H]AFB 1).

Groups l
NSA
Amount of AIAC
(µmol/ml plasma)

3.56 ± 0.22 2 a

[3H]AFB 1-AIAC adducts/µmol AIAC
(nmol AFB 1/µ.mol AIAC)

79.90

± 8.20 a

406.93

± 43.49 a

[3H]AFB 1 in AIAC/ml Plasma
(pmol AFB 1/ml plasma)
Amount of dose with AIAC
(% Dose/mnol AIAC)

6. 33

± 0.68 a

CSA

% Different

5.36

± 0.6 1 b

50.56

57 .00

± 4. 70b

28.70

420.00 ±.26.77 a

4.50

± 0.38 b

lNSA = Nonsupplemented AFB 1; CSA = Carnitine Supplemented AFB 1 .
2The values are mean ± SEM (n = 5 ). Values with different superscript letter are
significant (p S 0.05).

3 .2 1

28.90
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Table 4.11 Pl asma Carnitine Contents and [3H]AFB 1 -Acid Insoluble Acylcarnitine
Binding in Rats of Experiment 2 (24 h Post- [3H]AFB1).

Groups l
NSA
Nonesterified Carnitine (NEC)
(µmol/ml)

CSA

% Different

60. 17± 2.s 1b

5 1 . 68

± 0.92 a

5 . 29

Acid Insoluble Acylcamitine (AIAC)
13.86 ± 2.59 a
(µmol/ml)

17.90 ± 5.46 a

30.85

Total Camitine
(µmol/ml)

62.42 ± 2.64 a

86.48

± 3.0 1 b

3 8 .54

[3H]AFB 1 -AIAC adducts
(pmol AFB1/µmol AIAC)

15.02

17.20 ± 5.ssa

5. 8 1

199.74 ± 1 8.51 a

9.76

1. 17 ± 0.46 a

0.86

39.67 ± 1.2 32a

Acid Soluble Acylcamitine (ASAC)
(µmol/ml)
8.89 ± 1 .07a

[3H]AFB1 in AIAC/ml plasma
(pmol AFB 1/ ml pl asma)
Amount of dose with AIAC
(% Dose/runol AIAC)

± 2.58a

18 1 .98 ± 3 .4oa

1 . 16 ± 0.20a

8.42

l NSA = Nonsupplemented AFB1; CSA = Carnitine Supplemented AFB1.
2The values are me an ± SEM (n = 5 ). Values with different superscript letter are
signific ant (p � 0.05).
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[3H]AFB 1-AIAC adducts were also not significantly affected by carnitine
supplementation.
The amount of NEC in the liver 24 h after the dose of AFB 1 was 3 8.8% (p S 0.05)
higher in the CSA group as compared to th� NSA group (Table 4.8). The ASAC, AIAC,
and total carnitine were not statistically different between the NSA and CSA groups. The
binding of AFB 1 and amount of dose in AIAC in both groups were also not significantly
different.
Camitine treatment had significant effect on plasma carnitine concentrations in
Experiment 1 , but AFB 1 treatment did not (Table 4.9). Camitinc supplementation
increased NEC concentrations in the CSC group (74.65 µmol/ml) when compared to the
NSC group (5 1 .02 µmoVml). The ASAC fraction was not affected by carnitine
supplementation or the AFB 1 dose. The AIAC fraction was higher in the CSC rats than in
the NSC rats, as well as in the CSA rats when compared with NSA rats. As observed in
the liver, the AFB 1 was only bound to the AIAC fraction (Table 4. 1 0). The amount of
[3H]AFB 1-AIAC adducts and the amount of dose in AJAC were significantly higher in the
NSA group than in the CSA group. However, since the content of AIAC in the CSA
group was higher than in the NSA group, the amount of [3H]AFB t/ml of plasma was not
different between the two groups.
Plasma NEC and total camitine concentrations were significantly higher in the CSA
group than in the NSA group 24 h after the [3H]AFB 1 administration (Table 4. 1 1 ). There
was no difference in the amounts of ASAC, NEC and [3H]AFB 1 -AIAC adduct, and the
percentage of dose AIAC.
Table 4. 1 2 summarizes the [3H]AFB 1 concentrations in the liver, kidney and plasma
of rats 6 h after the dose cf [3H]AFB 1 . The amounts of [3H] AFB 1 found in the liver,
kidney, and plasma were not significantly different. Although the CSA group had 1 4.7%
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Table 4. 12 Tissue and Plasma [ 3 H]AFB 1 Concentrations
in Rats of Experiment 1 (6 h Post-[3H]AFB 1 ).
Groups l

NSA
Liver.
DPM ( l 0-4 )/g
nmole of AFB 1 /g

± 0.5 1 2a
± o.2sa

5.77
3.25

± o. soa
± o.2s a

14.7

1 .2 1
0.68

± 0. 14a
± o.osa

1 . 1 8 ± 0. 13a
0.66 ± 0.01 a

2.5

4.38
2.47

±
±

5.5 1 ± 0.73a
3. 10 ± 0.4 1 a

25 . 8

Plasma:

DPM ( l 0-4)/mI
nmole of AFB 1/ml

l NSA

% Different

6.77
3.8 1

Kidney:
DPM ( l 0-4 )/g
nmole of AFB 1 /g

CSA

0.25a
0. 14a

= Nonsupplemented AFB 1 ; CSA = Carnitine Supplemented AFB 1 .

2Toe values are mean ± SEM (n = 5 ) . Values with different superscript letter are significant
(p� 0.05 ) .
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less nmol of AFB1 in the liver and 25.8% more [3H]AFB 1 in the plasma than the NSA
group, the amounts were not statistically significant due to large standard deviation in the
results. The concentrations of [3 H]AFB 1 in the liver and kidney 24 h after the dose of
[3H]AFB1 were also not affected by the diet treatment (Table 4. 13). Howe·ver, CSA
plasma had 1 9.8% (p S 0.05) more [3H]AFB1 in the plasma than the plasma of the NSA
group.
The effects of carnitine on hepatic macromolecules 6 h after the dose of the AFB 1 are
shown in Table 4. 14 and 4. 1 5. Camitine had no effect on the RNA, DNA, and protein
content in all four groups Qf animal�. However, AFB 1 treatment significantly decreased
t!le liver RNA content in the NSA group as compared to NSC group, but RNA content in
the CSC and CSA groups remained relatively unchanged DNA and protein concentrations
were not affected by the AFB 1 treatment. The interaction of diet x AFB 1 was not
significant in affecting the macromolecule contents. Although the CSA group had 33.6%
less AFB 1-RNA adducts than NSA group, the difference was not significant (p S 0.06)
(Table 4. 1 5). In addition, diet treatment had no effect on the AFB1-protein adduct
concentrations. However, camitine supplemention markedly decreased (p S 0.0 1 ) the
amount of AFB 1-DNA adducts in rat livers as compared to nonsupplemented rats.
The effects of carnitine on the amount of hepatic macromolecules and AFB 1 macromolecules adducts 24 h after the dose of [3H]AFB 1 are shown in Table 4 . 16 .
Carnitine supplemented animals had higher amount of RNA, DNA and protein than the
NSA group. The quantities of AFB 1 binding to all three of the macromolecules were
significantly reduced in the camitine supplemented group.
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Tab le 4. 13 Tissue and Plasma [ 3 H]AFB 1 Concentrations
in Rats of Experiment 2 (24 h Post-[3 H]AFB 1) .
Groups l

NSA
Liver:
DPM (l0-4 )/g
nmole of AFB 1 /g
Kidney:
DPM ( 1�3 )/g
nmole of AFB 1 /g
Plasma:

DPM ( l 0-4)/mI
nmole of AFB 1/ml

l NSA

CSA

% Different

3.74 ± 0.35 2a
2. f l ± 0.20a

3.55 ± 0.22 a
2.00 ± 0. 1 2a

5.1

9.95 ± 0.6 1 a
0.56 ± o.o3 a

9.58 ± 0.22 a
0.54 ± 0.01a

3 .7

4.20 ± 0. 14a
2.37 ± o.osa

5.03
2.83

± 0.34 b

1 9. 8

± 0. 19 b

= Nonsupplemented AFB 1 ; CSA = Camitine Supplemented AFB 1 .

2Toe values are mean ± SEM (n = 5 ) . Values with different superscript letter are
significant (p;;? 0.05 ) .

Table 4.14 Effects of Diet and AFB 1 on Hepatic Macromolecule Contents
in Rats of Experiment 1 (6 h Post-AFB 1 ).

Groupsl
NSC

NSA

RNA (mg/g)

2.08 ± o.022ax

1 .8 1

DNA (mg/g)

2.90 ± o.14 ax
140. 9 ± 2.8 s ax

Protein (mg/g)

± o .09ay

csc

CSA

2.02 + 0.06axy

1.90 + o.osaxy

2. 63 ± 0. 1 6aX

2.93 ± o .24 ax

2.7 8 ± o.2 1ax

1 38.1 ± 5.4 8 ax

142.3 ± 4.11 ax

1 35.9 + 2.69aX

1 NSC = Nonsupplemented Control; NSA = Nonsupplemented AFB t ; CSC = Carnitine Supplemented; CSA = Camitine
Supplement AFB}.
2 Toe values are mean ± SEM (n = 5). Those values in a line bearing the different superscript letter (a - c) are statistically different (p �
0.05) due to diet treatment, and those bearing different superscript letters (x - z) are significantly different (p g),05) due to AFB 1 by a
two-way crossed ANOVA. Diet x AFB 1 interaction was not significant (p � 0.05) in all cases.
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Table 4.15 Effects of Camitine Supplemented Diet on Binding of AFB1 to Liver
Ma cromolecules in Rats of Experiment 1 (6 h Post-AFB 1).
Groups l
NSA

CSA

% Different

(ng AFB1/mg macromolecules)

± s.ss2 a

RNA

67 .34

DNA

21 .08 ± 0.98 a

Protein
l NSA

3.57 ± o.2 s a

44.73 ± 9.03a

33 .6

± 1.54 b

29.6

14.84

3.57 ± 0.44 a

0

= Nonsupplemented AFB1; CSA = Carnitine Supplemented AFB1 .

2Toe values are mean ± SEM (n = 5 ). Values with different superscript letter are
significant (p S 0.01).
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Table 4. 1 6 Effects of Camitine Supplemented Diet on Amount of Liver Macromolecules
and AFB 1 -Macromolecules Binding in Rats of Experiment 2 (24 h Post-AFB 1 ).
Groups l
NSA

CSA

RNA
mg RNA/g liver
ng AFB 1 /mg RNA

2. 8 1 ± 0.01 2 a
65.96 ± 4.96a

2.99 ± O.Q6 b
53.95 ± 2.26 b

6.4
1 8 .2

DNA
mg DNA/g liver
ng AFB 1 /mg DNA

2.47 ± 0.01 a
22.29 ± 2.58 a

2.16 ± o.o6 b
1 6.26 ± 1 .36 b

1 1 .7
27 .0

Protein
mg protein/g liver
ng AFB 1 /mg protein

1 48.03 ± 4.3 1 a
3.29 ± 0. 1 5 a

1 8 1 . 1 s ± 1 s. 1 3 b
3.04 ± 0. 1 3 b

22 .4
7.6

% Different

1 NSA = Nonsupplemented AFB 1 ; CSA = Camitine Supplemented AFB 1.
2The values are mean ± SEM (n = 5 ). Values with different superscript letter are
significant (p S 0.05).
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CHAPTER 5

DIS C US S IO N
5. 1

CARNITINE AND AFB1-INDUCED FATTY LIVER

One of the objectives of this study was to examine the effect of carnitine supplement
on AFB 1 -induced changes in the hepatic and plasma lipids. Camitine supplement
significantly reversed changes in lipid contents of the liver and plasma which are typically
induced by AFB 1 . Supplementary carnitine significantly inhibited AFB 1 -induced increase
in hepatic total lipid and triglycerides contents. This effect of camitine supports preliminary
observations (Sachan et al., unpublished) and was analogous to the amelioration of
ethanol-induced fatty liver (13,14,1 5) and fatty liver caused by lysine deficiency ( 101)
funher supporting the lipotropic actions of supplementary camitine. A diet low in
lipotropes (i.e. marginally deficient in choline and methionine, and lacking in folacin) has
been shown to cause a significant increase in the lipid content of rat liver (52). In poultry,
however, choline, inositol, vitamin E and B 12 supplementation of an adequate basal diet
did not significantly alter the fatty liver caused by aflatoxins (40).
Aflatoxin-induced decrease in plasma total lipid as well as triglyceride concentrations
(Table 4.4 and 4.5) is consistent with the studies reponed elsewhere (39 ,4 1 ). It has been
suggested that the lipid transport from the blood and peripheral tissues is impaired by
AFB 1 . Camitine appears to restore the transport system since CSA animals had
significantly higher lipid levels in the plasma and lower lipid levels in the liver. This
explanation is in accord with the proposed role of carnitine in inter-organ transport of fatty
acids and their metabolites (102). Protection of liver from fat accumulation caused by
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AFB 1 may also be aided by increased B-oxidation fo fatty acids caused by camitine. Actual
increase in plasma AIAC of the CSA rats (Table 4.9 and 4. 1 9 supports the argument that
exogenous camitine facilitated exit of fatty acids from the liver. Plasma acylcarnitine were
also increased in carnitine supplemented alcoholic rats where exogenous camitine
ameliorated hepatic steatosis ( 13). The increased excretion of medium-chain dicarboxy lie
acids in the urine of infants fed carnitine deficient formula (103) as well dicarboxylic
aciduria in infant fed carnitine-free formula ( 104) further lend support to camitine mediated
exit of fatty acid hypothesis.

5,2 CARNITINE AND AFB1-MACROMOLECULE

ADDUCTS FORMATION
In order to address the second objective of this study, examinations of AFB 1 macromolecule adducts were carried out The data strongly indicate that supplementary
camitine minimized binding of AFB 1 to liver RNA, DNA, and proteins (Table 4. 15 and
4. 16). This AFB 1 -DNA adduct was statistically lowered 6 h as well as 24 h post AFB 1
administration. Decrease in AFB 1 -DNA adduct suggest sthat camitine may modulate
caminogenic action of AFBl since AFB 1 -DNA adducts have been typically attributed to
cause carcinogenic response in animals (6,23,24,32,33) and humans ( 1 ,2,29,32) .
A 30% reduction in AFB 1 -DNA adduct formation due to camitine (Table 4. 15) is
comparable to 9-30% reduction by in vitro addition of riboflavin (46), far better than 9%
reduction by 60% food restriction (60), and 1 8% reduction by marginal deficiency of a
mixture of lipotropes (52). Choline deficiency increases (41 %) AFB 1 -DNA adduct
formation ( 105) which may be related to carnitine since choline deficiency also causes
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camitine deficiency ( 1 06). Cruciferous vegetables like Brussel sprouts (6 1 ) and chemical
compounds in them such as R-goitrin (64) have been shown to reduce AFB 1 -DNA adduct
50% and 43%, respectively. Food additives like BHA also reduced AFB 1-DNA adduct by
85% (64). Since many of these studies were done not under conditions identical to
camitine study, a direct comparison cannot be made.
Various mechanisms of action of different nutrients and food additives have been
proposed in conjunction with reported studies (52,6 1 ,63,64, 1 05, 1 06). Possible
mechanisms for interaction of camitine and AFB 1 may be proposed as follows: 1 )
carnitine enhances excretion of AFB 1; 2) carnitine retards AFB 1 metabolism; 3) carnitine
decreases half-life of AFB 1 binding to albumin; and/or 4) carnitine protects cell
membranes.

5.3 CARNITINE AND AFBl INTERACTION
It was hypothesized that camiti.ne by virtue of having an electrophilic nitrogen center
and a nucleophilic oxygen at pH 7 .4 may may attract AFB 1 and/or its metabolites. AFB 1
was not associated with NEC or ASAC, but AIAC had significant AFB 1 radioactivity
associated with it (Table 4.7 and 4.8). However, increases in AFB 1-AIAC complex in
CSA animals were not significant. These different may have become significant if one of
the group was fed a camitine deficient diet. It has been reported that AFB 1-albumin was
strengthened in the presence of long-chain fatty acids, namely palmitic, stearic, and oleic
acids, at the concentration range of 0.5 to 2 moles per mole albumin (57). Carnitine has
been found to conjugate with acidic xenobiotics, which are then excreted in the urine
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(89, 1 07). Carnitine supplementation, as observed in this study, had no significant effect
on the amounts of AFB 1 binding to AIAC.
Carnitine supplementation increased the concentrations of all liver carnitine fractions
and total carnitine as compared to the nonsupplemented animals, but the increases were not
statistically significant (Table 4.6). However, in the plasma, carnitine supplementation
markedly increased the NEC and total carnitine (Table 4.9). These data lead to the
suggestion that the liver will talce only a certain amount of the exogenous camitine and the
rest of it is goes to the blood and is transported to peripheral tissues or excreted in the
urine. It has been reported that the excretion of camitine in the urine was higher when the
animals were fed with camitine supplemented diet ( 100).
AFB 1 treatment increased the concentrations of NEC, ASAC and total camitine in
the liver, but had no effect in the plasma. In another words, AFB 1 causes the liver either tp
synthesize more camitine or get the camitine from extrahepatic tissues and/or exogenous
sources. Since camitine supplemented animals had an extra camitine pool in the blood, the
liver may take up this camitine to accomodate the effect of AFB 1 . The NSA group may
have to get camitine supply from the blood. As a result, although the CSA group had
lower plasma camitine than the CSC group, CSA camitine concentrations were still higher
than the NSC and NSA groups (Table 4.9). The higher concentrations of camitine in the
liver may explain the reason for the lower amounts of total lipid and triglyceride in the CSA
· group as compared to the NSA group. Similar observations were found when the rats
were fed with a liquid ethanol diet and carnitine (14).

5.4 CARNITINE AND AFB1 CONCENTRATION IN TISSUES AND PLASMA
Six hours �ter AFB 1 dosing, the amounts of AFB 1 in the liver, kidney, and plasma
were not statistically different in supplemented or non-supplemented animals. At 24 h after
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AFB1 administration, AFB1 concentrations were significantly lower in the plasma of the
CSA group than in the NSA group, but AFBt concentrations in the liver and kidney were
not significantly different. Modification of the method, especially in the digestion and
decolorization of the tissues, may reduce the deviation among the samples and produce
more conclusive results.

5,5 CARNITINE, BODY AND ORGANS WEIGHT AND AFB1 URINARY OUTPUT
This study found no significant changes in the body and organ weights in the rats
fed diet with or without supplementary camitine. These findings are similar to the study
.

done by Berger ( 1 00) who fed various levels of carnitine to Sprague-Dawley rats for 10 d.
'

As for the AFB1 treatment, obviously 6 h or 24 h after a s ingle dose ( 1 mg/kg) of AFB1
would not have much affect on the body or organ weights.
The 24-h total urinary output and the concentrations of AFB 1 found in the urine
were not significantly different in the NSA and CSA groups. It is important to point out
that in this urinary study, the sample size was small (n = 4) due to limited number of
metabolic cages. Fmthermore, there was too much deviation in the amount of urinary
output in the same group of animals (e.g., one of the rats in the NSA group excreted nearly
twice as much urine as rest of the rats in its group, and one of the rats in CSA group
excreted only 1/3 the amount of urine than the other 3 rats in its· group.) Therefore, limited
interpretations could be made about these results. However, in a different type of study,
carnitine supplementation was found to increase urinary volume in rats treated with
methanoi and isopropanol but not with ethylene glycol (83). The excretion of methanol and
isopropanol was significantly increased by carnitine supplementation. In a food restriction

77
study, the investigators observed that the 9 h urinary excretion of AFB 1 ( as % of dose)
was significantly higher in the food restricted than the ad lib. animals (60).
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CHAPTER 6

SUMMARY AND RECOMMENDATIONS

6.1 SUMMARY
The effects of camitine supplementation on AFB I -induced fatty liver and AFB I macromolecule adducts formation and effects of AFB I on camitine status were studied in
male Sprague-Dawley rats. Supplementary camitine reduced AFB 1 covalent binding to
hepatic macromolecules, namely RNA, DNA and protein. Furthermore, camitine
prevented the reduction of RNA, DNA and protein concentrations caused by AFB 1 .
Camitine supplement decreased the total lipid and triglyceride concentrations in the liver
caused by AFB 1 . In the plasma, supplementary camitine restored AFB 1 -induced decline
in total lipid and triglyceride concentrations. AFB 1 treatment of rats 6 h prior to sacrifice
was observed to cause significant increase in the liver NEC, ASAC, and total carnitine.
AFB 1 was found to conjugate with AIAC fraction, but not to NEC or the ASAC fractions.
The conjugation, however, was not significantly affected by supplemented carnitine. The
concentrations of AFB 1 determined in the liver, kidney and plasma were also not
statistically different in the camitine supplemented and nonsupplemented rats. Urinary
excretion of AFB 1 was not affected by camitine supplement. In conclusion,
supplementary camitine offered protection against AFB 1 -induced fatty liver and AFB 1 macromolecules adduct fonnation. Further studies may reveal anticarcinogenic potential of
carnitine.
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6,2 RECOMMENDATIONS
The following are some of the recommendations or areas for future studies:
1 . The design of the study should include on� group of animals that will be fed with
camitine deficient diet. Such a study would be expected to maximize effects of camitine in
cases of aflatoxin toxicity.
2. Determine the effects of AFB 1 on other major lipid fractions such as cholesterol,
phospholipids and free fatty acids which may reveal specific lipid fraction(s) affected by
camitine-AFB 1 treatment
3. Measure the influence of AFB 1 on the urinary excretion of camitine and
determine if the AFB 1 in the urine is conjugated with carnitine.
4. Determine the effects of carnitine on AFB 1 metabolism and 1\1FO enzymes
activities. These findings may provide the mechanism on how camitine inhibits the AFB 1 macromolecule adducts formation.
5. The number of animals should be increased to get more consistent data.
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A-3, 1 Dual Radioactivity Count,
D UAL LA BEL DPM (LS 1 801/3801)
Setting Up A Dual Label OPM Program
While the calculations for Dual Label DPM are much
more difficult than for single label , there is very little dif.
ference for the operator in the setup of the program. A
review of the si ngle label D P M section is recommended
before continuing. Figure 1 0-6 shows the series of ques
tions as they occu r on the LS-3801 CRT. LS 1801 ques
tions are identical but appear on the pri nter. The setup
for the Dual Label DPM programs is the same as the
si ngle label DPM except that four questions require an
answer for isotope 2 as well as isotppe 1 in the dual label
programs. These questions are: Unknown Normalization
Factor, U n known U nits, Half Life, and Standard DPM.
Setting Up The User Fite
The quench curve you store will determine the accuracy
of all the DPM answers you get from this program. It is
therefore recomended that you set up rigerous counting
conditions for the standards. These can be relaxed for
the unknowns as you see fi t. Count the sam ples long
enough to reach a 0.5% to 1% 2sigma statistical limit
(1 60,000 to 40,000 total cou nts). Turn AOC on and take
multiple H#'s (4 to 6). Chan nel 1 must be used for isotope
1, the lower energy isotope and Chan nel 2 must be used
for isotope 2, the higher energy isotope. ACM , if
avai lable, should be used .

The channel · settings are determined by the two
isotopes being counted. Usually, Channel 1 (the lower
energy isotope) is set to cover the entire isotope rangq
(0-400 for 1 H , for example). Chan nel 2 (the higher
energy isotope) is set so the lower window is the same
as the uppet window for the lower energy isotope. Th e
Channel 2 upper window is set for the isotope 2 end point
(400-670 for ••c in a 3 Hl'·C dual label}. Spectrum
Search can be used to determine window setti ngs for
unk nown isotopes.

Counting The Standards and U nknown!t
For Dual Label DPM programs you must have two sets
of standards, one for each isotope to be counted . Place
the lower energy isotope standard set i n a rack first.
Leave a space and put in the higher energy isotope
standara ·�et. Isotope 1 is always the lower energy
isotope and must be counted first. Isotope 2 is always the
higher energy isotope and must be counted second.
After placing the Isotope 2 standards in a rack, leave a
space and follo_w that with the u nknowns (Figure 1 0·7).
If
un knowns are fo be counted immediately, put in a
rack with a Halt card. Refer to 10.2 for prepari n g quench
curve!.

no

Explanation Of Printouts
The printout for Dual Label D PM reflects the in creased
complexity over Single Label DPM. However, the mean
ings of the printout are the same (Figure 10-8) . First, the
program summary is printed out. This is followed by the
data for Isotope 1 and Isotope 2 standards. Notice here
that two efficiencies are calculated for each isotope. One
efficiency is the isotope i n its own counting chan nel
(isotope 1 counted in channel 1 or isotope 2 in channel
2), and another efficiency is for the spillover of one
isotope into the other isotope's counting channel (isotope
1 counted in channel 2 or isotope 2 counted in chan nel
1). (See Section 1 .7 and Chapter 5). This correction for
four efficiencies leads to four EFFICI E NCY C U RVE
CO R R ELATIO N TA BLES and four sets of coefficients.
However. this complexity is handled by the instrument
so there is little difference to the operator except for the
printout.

The printout for the unknowns follows the quench
parameters. This printout includes the DPM for the two
isotopes and four counting efficiencies for each sample
(isotope 1 in chan nel 1, isotope 1 i n channel 2. iso�ope
2 in channel 1 , and isotope 2 in channel 2). The ratio of
isotope OPM's is also presented (Isotope 1/lsotope 2 and
Isotope 2/lsotope 1) since this is often of interest in dual
label experiments.

Source: Beckman LS 1801, 3801and 5801 Series Liquid Scintillation Systems Operating
Manual, Beckman Instruments, Irving, CA.
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A-3,1 Dual Radioactivity Count <Continued),
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A-3,2 Precaurionazy and Decontamination Procedures Purini Handlin& of Aflatoxins .
Aflatoxins have been shown to be extremely toxic and carcinogenic to number of
laboratory and domestic animals. Aflatoxin B 1 has been epidemiologically linked to human
liver cancer. Therefore, stringent safety measures should be exercised to prevent contact or
exposure with these toxins during handling. The following are the safety procedures and
recommendations as described by Stoloff et al. ( 1965), Fischbach et al. ( 1965), and
Castegnaro et al. (1982).

HANDLING OF DRY TOXINS

1. If possible, employ aflatoxins in solution since dry aflatoxins are electrostatic.
2. Always handle dry toxins under hoods that are properly ventilated and filtered.
3. Face masks and disposable rubber gloves should be worn.

DECONTAMINATION
a) Spilla&e
1. Cover area completly with 5-6% sodium hypochlorite (full strength chlorox, an
household bleach) dispensed from a wash-bottle.
2. If the surface cannot be wetted completely, cover the spillage with paper towels, and
wet the towels entirely with the bleach.
3. The amount of bleach used should be more than one-tenth of the volume of the spillage.
4. Contact time must be more than 30 seconds.
5. Wipe the surface off with paper towels.
6. Check area with UV lamp to ensure thorough decontamination is attained.
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A-3.2 Precautionazy and Decontamination Procedures Durini Handlioi of Aflatoxins
<Continued) .
b) Dust and powdered aflatoxins
1 . For inaccessible areas and before regular cleaning, vacuum the dust and treat the
contents of the vacuum bag with 5% NaOCl before disposing the bag.
2. Same treatment as for spillage if possible.
3. If not, wipe the surface with paper towels soaked in 5% NaOCl.

c) Hoods
1. Wipe the hoods regularly with 5% NaOCl.
2. At the end of the working day, decontaminate the hoods with chlorine gas produced by
adding equal volume of 5% NaOCl and 6N HCl.
3. Let the gas disperse for few minutes while the hood's door is shut. Exhaust overnight.

d) Laboratmy wares
1. Use 0.5% NaOCl for washing glass and other laboratory wares.
2. Ensure the entire surface of the wares is wetted and soaked for at least 30 seconds.
3. Soaking the wares in detergent + water for 8 hr could be used to substitute for the
bleach.
4. Rinse with acetone before drying.
5. Before disposing the solutions used for soaking, add full strength NaOCl (aLout one
tenth the volume of the soaking solutions).

Personnel
1 . Always use rubber gloves and protective masks when handling aflatoxins. Never
reused the gloves or masks.
2. Wear lab coat to prevent direct contact of possible spillage and dry toxins with clothes.
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A-3.2 Precaurionazy and Decontamination Procedures Durio� Handlin� of Aflatoxins
<Continued} .
3. Rubber gloves provide better protection then vinyl gloves for handling of aflatoxins in
dimethyl sulfoxide solution.
. 4. . Aflatoxin in chloroform can penetrate both rubber and vinyl gloves, therefore;
immediately change the gloves if the solution spilled onto the gloves.
5. If practical, wear thick or double pair of thin rubber gloves.
6. When skin is contaminated, wash it with 5% NaOCl before washing with soap and
water.
7. Sodium perborate with soap can be used if the skin is sensitive to the bleach.
8. If the mouth is contaminated, gaggle a mixed solution of 1 % sodium pcrborate and 1 %
sodium bicarbonate in water.
9. Contaminated garments should be soaked in 1% NaOCl (for cellulose fabrics) or 5%
sodium carbonate solution (for cotton or rayon fabrics) for 1 hr before laundering.

Disposal of Contaminated Materials and Samples
1 . Keep all samples and used gloves and masks in tightly closed containers, for examples
cans, jars, or plastic bags.
2. Bum the containers.
3. If burning is not possible, soaked the toxic materials in 5% NaOCl for 1/2 hr minimum.
4. Mixing might be necessary to get thorough soaking.
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Table A-4. 1 Percent Change in Total Lipid and Triglyceride Content due to
Diet and AFB 1 Treahnents in Rats of Experiment 1 (6 h Post-AFB 1 ).
LIVER
Total Lipids (%)

PLASMA
Triglycerides (%)

Total Lipids (%)

Triglycerides (%)

Nsc 1 - NsA 2

7.9

1 8 .7

17.3

30.5

NSC - Csc3

2.0

3.8

20.6

37.2

NSC - CSA 4

1 .6

11.1

6.4

6.9

NSA - CSC

9.2

12.5

4. 1

9 .6

NSA - CSA

8.9

6.4

1 3.2

34.0

CSC - CSA

0.3

7.0

1 8 .0

48.2

1 NSC = Nonsupplemented Control
2N SA = Nonsupplemented AFB 1 ;

3csc = Carnitine Supplemented;
4CSA = Carnitine Supplement AFB 1 .
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